{
  "directed": true,
  "graph": {
    "annotation_list": {},
    "annotation_pattern": {
      "Species": "^\\d+$"
    },
    "annotation_url": {
      "Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
      "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno",
      "CellLine": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno",
      "CellStructure": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno",
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno",
      "Subgraph": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno",
      "TextLocation": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"
    },
    "document_metadata": {
      "authors": "Sandra Spalek",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "copyright": "Copyright © 2018 Fraunhofer Institute SCAI, All rights reserved.",
      "description": "",
      "licenses": "CC BY 4.0",
      "name": "Clearance of Amyloid Beta and Tau in Alzheimer’s Disease:from Mechanisms to Therapy",
      "version": "1.0.1"
    },
    "namespace_pattern": {
      "DBSNP": "rs[0-9]+",
      "PUBCHEM": "^\\d+$",
      "TAXONOMY": "^\\d+$",
      "UNIPROT": "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\\.\\d+)?$"
    },
    "namespace_url": {
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns",
      "CONSO": "https://raw.githubusercontent.com/pharmacome/conso/501ceccdc9a27d97edbdc48a89ebe8e1dd3626e9/export/conso-names.belns",
      "DRUGBANK": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/drugbank-names.belns",
      "ECCODE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns",
      "FPLX": "https://raw.githubusercontent.com/sorgerlab/famplex/d9ec0526c20795146a9a6aef17496efe1a36cac6/export/famplex.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/go-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns",
      "HGNCGENEFAMILY": "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/external/hgnc.genefamily-names.belns",
      "HP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns",
      "INTERPRO": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/interpro-names.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/mesh-names.belns",
      "MGI": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns",
      "NCBIGENE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/entrez.belns",
      "PFAM": "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/pfam-names.belns",
      "RGD": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/rgd-names.belns"
    },
    "path": "tau/xin2018.bel",
    "pybel_version": "0.14.10"
  },
  "links": [
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Intracellular protein degradation is performed by UPS and ALS (Wong and Cuervo 2010",
      "key": "3efbaaed6b44a0fee45d020feca9e4b7",
      "line": 77,
      "relation": "increases",
      "source": 71,
      "target": 65
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Cell Nucleus": true,
          "Cytosol": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Under physiological conditions, UPS, located in the cytosol and the nucleus in eukaryotic cells, as a major intracellular short-lived protein degradation system (Schwartz and Ciechanover 2009), mediates the clearance of misfolded or other abnormally modified proteins with the help of ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2), ubiquitin ligase (E3), and the 26S proteasome for the sake of preventing the accumulation of toxic substances (Shang and Taylor 2011)",
      "key": "4b228d5a2111e13785246f6b2e34365d",
      "line": 89,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "regulates",
      "source": 71,
      "target": 59
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Cell Nucleus": true,
          "Cytosol": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Under physiological conditions, UPS, located in the cytosol and the nucleus in eukaryotic cells, as a major intracellular short-lived protein degradation system (Schwartz and Ciechanover 2009), mediates the clearance of misfolded or other abnormally modified proteins with the help of ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2), ubiquitin ligase (E3), and the 26S proteasome for the sake of preventing the accumulation of toxic substances (Shang and Taylor 2011)",
      "key": "a5788e807f17356594d80ff4888b4e70",
      "line": 90,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 71,
      "target": 132
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Cell Nucleus": true,
          "Cytosol": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Under physiological conditions, UPS, located in the cytosol and the nucleus in eukaryotic cells, as a major intracellular short-lived protein degradation system (Schwartz and Ciechanover 2009), mediates the clearance of misfolded or other abnormally modified proteins with the help of ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2), ubiquitin ligase (E3), and the 26S proteasome for the sake of preventing the accumulation of toxic substances (Shang and Taylor 2011)",
      "key": "291672ca9c931c6a8d61cb466631a96f",
      "line": 91,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 71,
      "target": 93
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Cell Nucleus": true,
          "Cytosol": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Under physiological conditions, UPS, located in the cytosol and the nucleus in eukaryotic cells, as a major intracellular short-lived protein degradation system (Schwartz and Ciechanover 2009), mediates the clearance of misfolded or other abnormally modified proteins with the help of ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2), ubiquitin ligase (E3), and the 26S proteasome for the sake of preventing the accumulation of toxic substances (Shang and Taylor 2011)",
      "key": "7170fa0cb74b3da7b56b769be312afe9",
      "line": 92,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 71,
      "target": 135
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Cell Nucleus": true,
          "Cytosol": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Under physiological conditions, UPS, located in the cytosol and the nucleus in eukaryotic cells, as a major intracellular short-lived protein degradation system (Schwartz and Ciechanover 2009), mediates the clearance of misfolded or other abnormally modified proteins with the help of ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2), ubiquitin ligase (E3), and the 26S proteasome for the sake of preventing the accumulation of toxic substances (Shang and Taylor 2011)",
      "key": "a312457d767ad765f0439cee9cf582b7",
      "line": 93,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 71,
      "target": 125
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Intracellular Space": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Intracellular Aβ clearance can be achieved through UPS and ALS, and extracellular Aβ is degraded by glial phagocytosis, such as microglia, astrocytes, and proteases from neurons and astrocytes (Fig. 2)",
      "key": "f5d74584fb60d01b647b3e9eb4c613b5",
      "line": 190,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 71,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Intracellular Space": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Intracellular Aβ degradation pathways mainly contain two major pathways: UPS and ALS (Vilchez et al. 2014)",
      "key": "3a5fd1aad51e76100acfd80f31b3faab",
      "line": 213,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 71,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Synapses": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Dysfunction of UPS brings about the deposition of hyperphosphorylated tau oligomers in synapses (Tai et al. 2012)",
      "key": "03f7961a000cb95b82b6ccca4e2ccf31",
      "line": 721,
      "relation": "decreases",
      "source": 71,
      "target": 87
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Intracellular protein degradation is performed by UPS and ALS (Wong and Cuervo 2010",
      "key": "cf4879ef754673a5dcf1e1e9b90429ec",
      "line": 78,
      "relation": "increases",
      "source": 69,
      "target": 65
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Intracellular Space": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Intracellular Aβ clearance can be achieved through UPS and ALS, and extracellular Aβ is degraded by glial phagocytosis, such as microglia, astrocytes, and proteases from neurons and astrocytes (Fig. 2)",
      "key": "7cd1753c7b6a7d43d01713782b4e410e",
      "line": 191,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 69,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Intracellular Space": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Intracellular Aβ degradation pathways mainly contain two major pathways: UPS and ALS (Vilchez et al. 2014)",
      "key": "d742d2360812e0d82cf4ecaf4e737c75",
      "line": 214,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 69,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "In addition, there is accumulating evidence to prove that Aβ can be cleared by ALS.",
      "key": "0c2112475c2e2e49341d527a2997f8b4",
      "line": 247,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 69,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "On the one hand, it is beneficial to the clearance of tau aggregates",
      "key": "e3d84498409122594137cb03cd3174bf",
      "line": 728,
      "relation": "decreases",
      "source": 69,
      "target": 34
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "On the other hand, it brings about tau fragmentation into pro-aggregating forms due to the failure of F1 to enter the lysosome",
      "key": "ee6f6685d1ee705e826b78cf66f679a1",
      "line": 736,
      "relation": "increases",
      "source": 69,
      "target": 115
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Cell Nucleus": true,
          "Cytosol": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Under physiological conditions, UPS, located in the cytosol and the nucleus in eukaryotic cells, as a major intracellular short-lived protein degradation system (Schwartz and Ciechanover 2009), mediates the clearance of misfolded or other abnormally modified proteins with the help of ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2), ubiquitin ligase (E3), and the 26S proteasome for the sake of preventing the accumulation of toxic substances (Shang and Taylor 2011)",
      "key": "62e7b23f629e6dd428cd5e3bea598b65",
      "line": 94,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 132,
      "target": 59
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Cell Nucleus": true,
          "Cytosol": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Under physiological conditions, UPS, located in the cytosol and the nucleus in eukaryotic cells, as a major intracellular short-lived protein degradation system (Schwartz and Ciechanover 2009), mediates the clearance of misfolded or other abnormally modified proteins with the help of ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2), ubiquitin ligase (E3), and the 26S proteasome for the sake of preventing the accumulation of toxic substances (Shang and Taylor 2011)",
      "key": "b6197d311309115ecc904e2dbaa63578",
      "line": 95,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 93,
      "target": 59
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Cell Nucleus": true,
          "Cytosol": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Under physiological conditions, UPS, located in the cytosol and the nucleus in eukaryotic cells, as a major intracellular short-lived protein degradation system (Schwartz and Ciechanover 2009), mediates the clearance of misfolded or other abnormally modified proteins with the help of ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2), ubiquitin ligase (E3), and the 26S proteasome for the sake of preventing the accumulation of toxic substances (Shang and Taylor 2011)",
      "key": "efad891faf25f91cfb1c710a28ac3108",
      "line": 97,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 125,
      "target": 59
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Cell Nucleus": true,
          "Cytosol": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Under physiological conditions, UPS, located in the cytosol and the nucleus in eukaryotic cells, as a major intracellular short-lived protein degradation system (Schwartz and Ciechanover 2009), mediates the clearance of misfolded or other abnormally modified proteins with the help of ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2), ubiquitin ligase (E3), and the 26S proteasome for the sake of preventing the accumulation of toxic substances (Shang and Taylor 2011)",
      "key": "2009cffa236fb6afc867add454fddc78",
      "line": 96,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 52,
      "target": 59
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "And autophagy-lysosomal activity is induced via two signal pathways: mammalian target of rapamycin (mTOR)-dependent pathway and mTORindependent pathway (Tan et al. 2014b)",
      "key": "82335d324b26b763aab9358d17724e66",
      "line": 113,
      "relation": "increases",
      "source": 81,
      "target": 69
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Central Nervous System": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Microglia, one type of glial cells, the equivalent of the macrophages that exist in the brain and spinal cord, is the first and also the main line of immune defense in CNS",
      "key": "b907ee970a6157aab2b95c4bada44a6a",
      "line": 121,
      "relation": "increases",
      "source": 57,
      "subject": {
        "modifier": "Activity"
      },
      "target": 67
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Activated microglia has a double effect on AD progression (Li et al. 2014). On the one hand, they can release some proinflammatory cytokines, stimulating inflammatory response and ultimately leading to neuronal injuries and death",
      "key": "a9af35b8afa8f6b1b6984e20afdc5d5c",
      "line": 132,
      "relation": "increases",
      "source": 57,
      "subject": {
        "modifier": "Activity"
      },
      "target": 66
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Activated microglia has a double effect on AD progression (Li et al. 2014). On the one hand, they can release some proinflammatory cytokines, stimulating inflammatory response and ultimately leading to neuronal injuries and death",
      "key": "f3dffadd2121842897d8bd0d42047e5c",
      "line": 133,
      "relation": "increases",
      "source": 57,
      "subject": {
        "modifier": "Activity"
      },
      "target": 68
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "On the other hand, they may show beneficial effects via facilitating aberrant protein clearance by means of microglial migration to the damaged, aberrant area, and phagocytosis of unnecessary materials in the early stages of AD",
      "key": "4bcb72ba3ce8d20accdc138af117531f",
      "line": 143,
      "relation": "increases",
      "source": 57,
      "subject": {
        "modifier": "Activity"
      },
      "target": 77
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Microglial cells, the key immune cells of the brain, play an important part in the phagocytosis of Aβ",
      "key": "99f24383631d93b82f077a84b43020e8",
      "line": 373,
      "relation": "increases",
      "source": 57,
      "target": 77
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Extracellular Space": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Intracellular Aβ clearance can be achieved through UPS and ALS, and extracellular Aβ is degraded by glial phagocytosis, such as microglia, astrocytes, and proteases from neurons and astrocytes (Fig. 2)",
      "key": "7ff4e6560c3c3ff0bd0f12deea711ba1",
      "line": 193,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 77,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Microglial cells, the key immune cells of the brain, play an important part in the phagocytosis of Aβ",
      "key": "8fb8cbfbf8457dd08446f1e11325d9da",
      "line": 374,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 77,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Aβ is cleared by receptor-mediated microglial phagocytosis and degradation, such as scavenger receptors, chemokine-like receptor 1, toll-like receptors, and G protein-coupled receptors including formyl peptide receptor 2 (Yu and Ye 2015)",
      "key": "a11b19c20c5fb137fbabb9c05c3fc1bb",
      "line": 383,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 77,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "In addition, triggering receptor expressed on myeloid cells 2 (TREM2), ATP-binding cassette transporter A7, and CD33 also play key roles in microglial phagocytosis",
      "key": "9b0730d8426c6ecfd3b1bb0f018fcaba",
      "line": 395,
      "relation": "association",
      "source": 77,
      "target": 129
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "In addition, triggering receptor expressed on myeloid cells 2 (TREM2), ATP-binding cassette transporter A7, and CD33 also play key roles in microglial phagocytosis",
      "key": "5b221490273f92a700b41b61a0b5da7a",
      "line": 396,
      "relation": "association",
      "source": 77,
      "target": 94
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "In addition, triggering receptor expressed on myeloid cells 2 (TREM2), ATP-binding cassette transporter A7, and CD33 also play key roles in microglial phagocytosis",
      "key": "c103439f9c8f6162d542eba7bfe8a805",
      "line": 397,
      "relation": "association",
      "source": 77,
      "target": 103
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "In addition, Aβ1–42 can increase the expression of TREM2, a surface signaling receptor in microglia, and the up-regulation of TRME2 can facilitate microglial phagocytosis of Aβ1–42",
      "key": "197a6b8e2b4b7279b83e9e51d4b99dbe",
      "line": 407,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 77,
      "target": 6
    },
    {
      "annotations": {
        "Cell": {
          "microglial cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "There was direct evidence to show that microglial phagocytosis plays a pivotal role in clearance of tau in vitro and in vivo (Bolos et al. 2015)",
      "key": "9e0e0e76228b3c78cfd603597f7de324",
      "line": 779,
      "relation": "decreases",
      "source": 77,
      "target": 114
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "However, some proteins fail to be transported out of the brain through intercellular tight junctions, and can only be transported into blood by transporters expressed in the capillary endothelium",
      "key": "a521ee269d36c190bcbcbe20535813be",
      "line": 163,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "Brain",
            "namespace": "MESH"
          },
          "toLoc": {
            "name": "Blood",
            "namespace": "MESH"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "decreases",
      "source": 51,
      "target": 59
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Unfortunately, the glymphatic system may be impaired due to the loss of AQP4 after traumatic brain injury (Iliff et al. 2014)",
      "key": "6d3327d249ac34e32d37326d9fb3547d",
      "line": 170,
      "relation": "decreases",
      "source": 138,
      "target": 100
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "After traumatic brain injury (TBI), the expression and location of AQP4 will change, inducing its dysfunction (Ren et al. 2013)",
      "key": "a4ecd7af840d15512d7f719e5dcba64e",
      "line": 627,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 138,
      "target": 100
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Extracellular Fluid": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "It has been reported that ISF tau can be eliminated by the glymphatic system and the function of this clearance mechanism may be impaired due to the loss of AQP4 after TBI, which ultimately accelerates tau accumulation (Iliff et al.2014)",
      "key": "03d019506a50e8a86ecbbce3a93650bf",
      "line": 791,
      "relation": "decreases",
      "source": 138,
      "target": 100
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Unfortunately, the glymphatic system may be impaired due to the loss of AQP4 after traumatic brain injury (Iliff et al. 2014)",
      "key": "c7a95c091ca594d1f73af23fc31542bd",
      "line": 171,
      "relation": "decreases",
      "source": 138,
      "target": 38
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Extracellular Fluid": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "It has been reported that ISF tau can be eliminated by the glymphatic system and the function of this clearance mechanism may be impaired due to the loss of AQP4 after TBI, which ultimately accelerates tau accumulation (Iliff et al.2014)",
      "key": "2e7d70b979189e828368b4ab11e7e9b2",
      "line": 793,
      "relation": "decreases",
      "source": 138,
      "target": 38
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Extracellular Fluid": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "It has been reported that ISF tau can be eliminated by the glymphatic system and the function of this clearance mechanism may be impaired due to the loss of AQP4 after TBI, which ultimately accelerates tau accumulation (Iliff et al.2014)",
      "key": "c9f6ad1144e3e39e3895b333bcd5bf13",
      "line": 792,
      "relation": "increases",
      "source": 138,
      "target": 114
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Unfortunately, the glymphatic system may be impaired due to the loss of AQP4 after traumatic brain injury (Iliff et al. 2014)",
      "key": "b13e9a1b87d29807cc8fe0b06ba4bcca",
      "line": 172,
      "relation": "increases",
      "source": 100,
      "target": 38
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Extracellular Fluid": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "It has been reported that ISF tau can be eliminated by the glymphatic system and the function of this clearance mechanism may be impaired due to the loss of AQP4 after TBI, which ultimately accelerates tau accumulation (Iliff et al.2014)",
      "key": "a448f8a29a033143c3e4f5f716f80e66",
      "line": 790,
      "relation": "increases",
      "source": 100,
      "target": 38
    },
    {
      "annotations": {
        "Cell": {
          "astrocyte": true
        },
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "In addition, Jeffrey J. Iliff et al. have demonstrated that the Aβ in brain interstitium can be eliminated from the parenchyma by the bulk flow of interstitial fluid, which also depends on a water channel aquaporin-4 (AQP4) expressed in astrocyte endfeet",
      "key": "53cc9169831aa9345428a9cf89885aea",
      "line": 602,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "association",
      "source": 100,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Brain": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Consistent with the conclusion above, there is evidence that glymphatic drainage of ISF bulk flow relying on water channel AQP4 can decrease the levels of Aβ in brain (Iliff et al. 2012)",
      "key": "3801b2aad60a528576e1615debe4bae2",
      "line": 611,
      "relation": "decreases",
      "source": 100,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "In the meanwhile, a study supported this idea that AQP4 deficiency can reduce the rate of Aβ clearance via glymphatic pathway (Iliff and Nedergaard 2013)",
      "key": "307953def773ff97ca0bda9f8d658737",
      "line": 620,
      "relation": "decreases",
      "source": 100,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "In the meanwhile, a study supported this idea that AQP4 deficiency can reduce the rate of Aβ clearance via glymphatic pathway (Iliff and Nedergaard 2013)",
      "key": "2f57a2ca66a0f51bf320fee78f3f1982",
      "line": 619,
      "relation": "decreases",
      "source": 38,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Extracellular Fluid": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "It has been reported that ISF tau can be eliminated by the glymphatic system and the function of this clearance mechanism may be impaired due to the loss of AQP4 after TBI, which ultimately accelerates tau accumulation (Iliff et al.2014)",
      "key": "a8a617bc577dfbb9114bb00797d8629d",
      "line": 789,
      "relation": "decreases",
      "source": 38,
      "target": 114
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Under normal conditions, Aβ production in brain parenchyma results from hydrolyzing amyloid precursor proteins via beta-secreted enzymes and gamma-secreted enzymes, and the most common subtypes of Aβ in human body are Aβ1–40 and Aβ1–42",
      "key": "729432cba439bc3f371be2742d90a4d7",
      "line": 180,
      "relation": "increases",
      "source": 80,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "The excessive deposition of Aβ also induces oxidative stress and mitochondrial dysfunction, which fails to offer ATP for the degradation of targeted proteins by UPS in yeast (Chen and Petranovic 2015)",
      "key": "4e9cf40f98bb568f9856b2f9d5c2736e",
      "line": 240,
      "relation": "increases",
      "source": 7,
      "target": 72
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Meanwhile, an animal experiment showed that IDE expression will descend with age and diabetes, then resulting in Aβ deposition (Kochkina et al. 2015)",
      "key": "7e142b8df37a64b20cc486e0a4df37e7",
      "line": 324,
      "relation": "positiveCorrelation",
      "source": 7,
      "target": 74
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Meanwhile, an animal experiment showed that IDE expression will descend with age and diabetes, then resulting in Aβ deposition (Kochkina et al. 2015)",
      "key": "d47bd3592e7a38dc2bb29fb52163837c",
      "line": 326,
      "relation": "positiveCorrelation",
      "source": 7,
      "target": 139
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Among MMPs, MMP-2, -3 and -9, stimulated by Aβ, play important roles in degrading Aβ (Wang et al. 2014)",
      "key": "251976970b3f36b518c73914cbc826d5",
      "line": 362,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 7,
      "target": 118
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Among MMPs, MMP-2, -3 and -9, stimulated by Aβ, play important roles in degrading Aβ (Wang et al. 2014)",
      "key": "f4a559a73a868f4f55f2a48e00c7da12",
      "line": 364,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 7,
      "target": 119
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Among MMPs, MMP-2, -3 and -9, stimulated by Aβ, play important roles in degrading Aβ (Wang et al. 2014)",
      "key": "bfa2663394bd0190965377b3cd4412b9",
      "line": 366,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 7,
      "target": 120
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "By collecting time-matched blood samples from cerebral vein, femoral vein, and radial artery in patients to measure the concentration of Aβ for every blood sample and figure out the turnover of it from vein to artery, it has been shown that transport of Aβ from brain to blood via the BBB and CSF absorption accounts for half of the total clearance of Aβ in CNS in humans, and furthermore, the clearance rate of Aβ via the BBB and CSF absorption accounts for the same proportion (Roberts et al. 2014)",
      "key": "f820684251a11e7b260048f4d0132a01",
      "line": 460,
      "relation": "decreases",
      "source": 7,
      "subject": {
        "effect": {
          "fromLoc": {
            "name": "Brain",
            "namespace": "MESH"
          },
          "toLoc": {
            "name": "Blood",
            "namespace": "MESH"
          }
        },
        "modifier": "Translocation"
      },
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "In addition, Aβ deposition in CP also blocks CSF production in AD (Serot et al. 2012).",
      "key": "99640f5ee6c826cad43d6b221615fd43",
      "line": 573,
      "relation": "decreases",
      "source": 7,
      "target": 41
    },
    {
      "key": "5bc6dc0e1be7286a0c0d8569189d67b5",
      "relation": "partOf",
      "source": 7,
      "target": 82
    },
    {
      "annotations": {
        "Cell": {
          "astrocyte": true
        },
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "In addition, Jeffrey J. Iliff et al. have demonstrated that the Aβ in brain interstitium can be eliminated from the parenchyma by the bulk flow of interstitial fluid, which also depends on a water channel aquaporin-4 (AQP4) expressed in astrocyte endfeet",
      "key": "d0c26847c853c875690571ec3174012e",
      "line": 602,
      "relation": "association",
      "source": 7,
      "subject": {
        "modifier": "Degradation"
      },
      "target": 100
    },
    {
      "key": "7ebd1f49afa0aaf2bfa49073923e7e64",
      "relation": "partOf",
      "source": 7,
      "target": 85
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Under normal conditions, Aβ production in brain parenchyma results from hydrolyzing amyloid precursor proteins via beta-secreted enzymes and gamma-secreted enzymes, and the most common subtypes of Aβ in human body are Aβ1–40 and Aβ1–42",
      "key": "7b0b647072225e39966fdbc39e530abd",
      "line": 181,
      "relation": "increases",
      "source": 101,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Aβ in periphery is mainly cleared by blood components, such as red cells (RBCs) and monocytes, or some tissues and organs, such as the liver and kidney (Fig. 2)",
      "key": "6f5c9c4129236709b2a678baa7025b73",
      "line": 203,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 54,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Dietary pre-administration of docosahexaenoic acid prevents RBCs from oxidative damage due to its antioxidative characteristic and also increases Aβ degradation by RBC in a lipid raft-dependent manner (Hashimoto et al. 2015)",
      "key": "4c62334b89cbb04e9814d55c88633306",
      "line": 1068,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 54,
      "target": 7
    },
    {
      "key": "1e23d238f5aee3f2bf2b324c8f2de7ae",
      "relation": "partOf",
      "source": 54,
      "target": 84
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Aβ in periphery is mainly cleared by blood components, such as red cells (RBCs) and monocytes, or some tissues and organs, such as the liver and kidney (Fig. 2)",
      "key": "2ec3d7537fc1225ebe3a1dbea6dfa5db",
      "line": 204,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 58,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Monocytes in peripheral blood have been demonstrated to play an important role in clearing Aβ that diffuses from brain to blood (Halle et al. 2015)",
      "key": "daa31da03f008e324210f43358631c7c",
      "line": 692,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 58,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Aβ in periphery is mainly cleared by blood components, such as red cells (RBCs) and monocytes, or some tissues and organs, such as the liver and kidney (Fig. 2)",
      "key": "ef757f6558f160da6dfdf1aca0020ed7",
      "line": 205,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 56,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Arteries": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "By measuring Aβ levels in superior vena cava and inferior vena cava, it is clear that Aβ levels are getting lower and lower along the direction of the vein blood flow, and the contents of Aβ40 and total Aβ in artery are significantly less than those in vein, suggesting a part of Aβ40 and total Aβ can be cleared by peripheral organs and tissues, such as the liver, kidney, skin, and the gastrointestinal tract, although there is no change in Aβ42 concentrations (Xiang et al. 2015)",
      "key": "14a5923b160eaab7b5960983ccd01b17",
      "line": 658,
      "relation": "decreases",
      "source": 56,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Among these peripheral organs and tissues mentioned above, the liver and kidney are considered to be the major organs for the clearance of Aβ in periphery (Ghiso et al. 2004)",
      "key": "3d3a773145f4e925f7db66432243859c",
      "line": 677,
      "relation": "decreases",
      "source": 56,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Arteries": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "By measuring Aβ levels in superior vena cava and inferior vena cava, it is clear that Aβ levels are getting lower and lower along the direction of the vein blood flow, and the contents of Aβ40 and total Aβ in artery are significantly less than those in vein, suggesting a part of Aβ40 and total Aβ can be cleared by peripheral organs and tissues, such as the liver, kidney, skin, and the gastrointestinal tract, although there is no change in Aβ42 concentrations (Xiang et al. 2015)",
      "key": "6034d0862f8c1223d76f517fa1ee66d0",
      "line": 659,
      "relation": "decreases",
      "source": 56,
      "target": 5
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Arteries": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "By measuring Aβ levels in superior vena cava and inferior vena cava, it is clear that Aβ levels are getting lower and lower along the direction of the vein blood flow, and the contents of Aβ40 and total Aβ in artery are significantly less than those in vein, suggesting a part of Aβ40 and total Aβ can be cleared by peripheral organs and tissues, such as the liver, kidney, skin, and the gastrointestinal tract, although there is no change in Aβ42 concentrations (Xiang et al. 2015)",
      "key": "af940a20b6f854089c0ee8df26b89410",
      "line": 660,
      "relation": "causesNoChange",
      "source": 56,
      "target": 6
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Aβ in periphery is mainly cleared by blood components, such as red cells (RBCs) and monocytes, or some tissues and organs, such as the liver and kidney (Fig. 2)",
      "key": "fdaeabf5d6d94e282aa82a3bc27ddaa5",
      "line": 206,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 55,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Arteries": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "By measuring Aβ levels in superior vena cava and inferior vena cava, it is clear that Aβ levels are getting lower and lower along the direction of the vein blood flow, and the contents of Aβ40 and total Aβ in artery are significantly less than those in vein, suggesting a part of Aβ40 and total Aβ can be cleared by peripheral organs and tissues, such as the liver, kidney, skin, and the gastrointestinal tract, although there is no change in Aβ42 concentrations (Xiang et al. 2015)",
      "key": "3361fe77f01062b63cda097af9939b20",
      "line": 661,
      "relation": "decreases",
      "source": 55,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Among these peripheral organs and tissues mentioned above, the liver and kidney are considered to be the major organs for the clearance of Aβ in periphery (Ghiso et al. 2004)",
      "key": "05b52d9d08a275b9885a046664207cf8",
      "line": 678,
      "relation": "decreases",
      "source": 55,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Arteries": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "By measuring Aβ levels in superior vena cava and inferior vena cava, it is clear that Aβ levels are getting lower and lower along the direction of the vein blood flow, and the contents of Aβ40 and total Aβ in artery are significantly less than those in vein, suggesting a part of Aβ40 and total Aβ can be cleared by peripheral organs and tissues, such as the liver, kidney, skin, and the gastrointestinal tract, although there is no change in Aβ42 concentrations (Xiang et al. 2015)",
      "key": "0db107215f8c1133ceaaac6bc09c9910",
      "line": 662,
      "relation": "decreases",
      "source": 55,
      "target": 5
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Arteries": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "By measuring Aβ levels in superior vena cava and inferior vena cava, it is clear that Aβ levels are getting lower and lower along the direction of the vein blood flow, and the contents of Aβ40 and total Aβ in artery are significantly less than those in vein, suggesting a part of Aβ40 and total Aβ can be cleared by peripheral organs and tissues, such as the liver, kidney, skin, and the gastrointestinal tract, although there is no change in Aβ42 concentrations (Xiang et al. 2015)",
      "key": "50ea6a16210bbc38ebc9ca945ec8668a",
      "line": 663,
      "relation": "causesNoChange",
      "source": 55,
      "target": 6
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "However, their dysfunction in AD due to some factors will reduce Aβ clearance",
      "key": "b2ce9c93a7eea294328f9b68a2ffefa2",
      "line": 221,
      "relation": "decreases",
      "source": 137,
      "target": 71
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "However, their dysfunction in AD due to some factors will reduce Aβ clearance",
      "key": "b412d3bb79662f42be7a3c67940263c5",
      "line": 222,
      "relation": "decreases",
      "source": 137,
      "target": 69
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "However, their dysfunction in AD due to some factors will reduce Aβ clearance",
      "key": "7ddc97369b760ea9e00b3f4e9758e5c0",
      "line": 223,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "decreases",
      "source": 137,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "However, recently, it has been reported that the expression and transport activity of P-gp are impaired in sporadic AD as a result of its ubiquitination, internalization, and proteasome-dependent degradation derived from Aβ40 (Chiu et al. 2015; Hartz et al. 2016), which will result in Aβ deposition",
      "key": "5db01ec5ca71b2778a1e214516f6ffa4",
      "line": 527,
      "relation": "increases",
      "source": 137,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "In addition, ACE expression also enhances Aβ clearance, and the levels and activity of ACE are elevated in AD brains (Barnes et al. 1991; Hemming and Selkoe 2005)",
      "key": "811d2655ab5b86e414054b6b6d19a400",
      "line": 345,
      "object": {
        "modifier": "Activity"
      },
      "relation": "positiveCorrelation",
      "source": 137,
      "target": 96
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "However, the levels and activity of plasmin are reduced in AD brains (Ledesma et al. 2000)",
      "key": "57c2e07b97a804e030570c6ea194d0e4",
      "line": 355,
      "relation": "negativeCorrelation",
      "source": 137,
      "target": 126
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "However, the levels and activity of plasmin are reduced in AD brains (Ledesma et al. 2000)",
      "key": "f2237dc6bdad844df064ea7a0ea5499d",
      "line": 356,
      "object": {
        "modifier": "Activity"
      },
      "relation": "negativeCorrelation",
      "source": 137,
      "target": 126
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "And in AD, the decreasing expression of PICALM in brain endothelium reduces Aβ clearance (Zhao et al. 2015b)",
      "key": "7af0b8abf50a0dac19ac9be7a28ee2c5",
      "line": 485,
      "relation": "negativeCorrelation",
      "source": 137,
      "target": 122
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "However, recently, it has been reported that the expression and transport activity of P-gp are impaired in sporadic AD as a result of its ubiquitination, internalization, and proteasome-dependent degradation derived from Aβ40 (Chiu et al. 2015; Hartz et al. 2016), which will result in Aβ deposition",
      "key": "5c8e56ea618df1b01de60650e873a40d",
      "line": 526,
      "relation": "decreases",
      "source": 137,
      "target": 95
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "In a similar manner, a recent experiment indicated that water influx into the CSF is significantly reduced in AD-patients, which may impair Aβ clearance (Suzuki et al. 2015)",
      "key": "b70d0bd2b3344f99fd8b03b0b95bfd82",
      "line": 566,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "extracellular region",
            "namespace": "GO"
          },
          "toLoc": {
            "name": "Cerebrospinal Fluid",
            "namespace": "MESH"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "decreases",
      "source": 137,
      "target": 32
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "As is known, the accumulation of frameshift ubiquitin-B (UBB) mutant protein UBB (+1) can block the 26S proteasome in cell lines, and then can reduce Aβ clearance (Hope et al. 2003)",
      "key": "51c4e04ff442ab76ab255776d5aa1fb7",
      "line": 231,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 134,
      "target": 125
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "As is known, the accumulation of frameshift ubiquitin-B (UBB) mutant protein UBB (+1) can block the 26S proteasome in cell lines, and then can reduce Aβ clearance (Hope et al. 2003)",
      "key": "59847740a6500427fa876b3d76c4f07d",
      "line": 232,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "decreases",
      "source": 134,
      "target": 7
    },
    {
      "key": "b8079a3b2966c288186cf1dac2c14037",
      "relation": "hasVariant",
      "source": 133,
      "target": 134
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Transcriptional factor EB downregulates Aβ levels by affecting autophagy-lysosome (Zhang and Zhao 2015)",
      "key": "6891e570d5ace7457931d95491d5f448",
      "line": 253,
      "relation": "decreases",
      "source": 128,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Astrocytes": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Xiao et al. have also obtained the consistent conclusion that transcriptional factor EB, a master regulator of lysosome biogenesis, improves lysosomal function in astrocytes, which may promote Aβ clearance and attenuate plaque pathogenesis (Xiao et al. 2014)",
      "key": "ce6d158b009267631d68499ff5683760",
      "line": 263,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 128,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "For example, like Aβ, clearance of pTau/NFT also can be regulated by TFEB, which increases the activity of autophagy and lysosome (Polito et al. 2014)",
      "key": "fd8e34ba911964ae40abb817a2683bdf",
      "line": 745,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "regulates",
      "source": 128,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Astrocytes": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Xiao et al. have also obtained the consistent conclusion that transcriptional factor EB, a master regulator of lysosome biogenesis, improves lysosomal function in astrocytes, which may promote Aβ clearance and attenuate plaque pathogenesis (Xiao et al. 2014)",
      "key": "2ac7ecbe726a3898743907ee5049583f",
      "line": 262,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 128,
      "target": 35
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "For example, like Aβ, clearance of pTau/NFT also can be regulated by TFEB, which increases the activity of autophagy and lysosome (Polito et al. 2014)",
      "key": "9ad1cfe54c0c2162aa3459f5bbf467de",
      "line": 747,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 128,
      "target": 35
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Astrocytes": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Xiao et al. have also obtained the consistent conclusion that transcriptional factor EB, a master regulator of lysosome biogenesis, improves lysosomal function in astrocytes, which may promote Aβ clearance and attenuate plaque pathogenesis (Xiao et al. 2014)",
      "key": "e0ea3e14ae03fb8c1960ebf889246b0b",
      "line": 264,
      "relation": "decreases",
      "source": 128,
      "target": 140
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "For example, like Aβ, clearance of pTau/NFT also can be regulated by TFEB, which increases the activity of autophagy and lysosome (Polito et al. 2014)",
      "key": "97666b4a75835d47423a3856ecdd49f9",
      "line": 743,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "regulates",
      "source": 128,
      "target": 47
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "For example, like Aβ, clearance of pTau/NFT also can be regulated by TFEB, which increases the activity of autophagy and lysosome (Polito et al. 2014)",
      "key": "4392b543df6dec3cb09a57b25c88f7c5",
      "line": 744,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "regulates",
      "source": 128,
      "target": 116
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "For example, like Aβ, clearance of pTau/NFT also can be regulated by TFEB, which increases the activity of autophagy and lysosome (Polito et al. 2014)",
      "key": "980e844aa8f518f935b4a3eba15514a5",
      "line": 746,
      "relation": "increases",
      "source": 128,
      "target": 75
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "The proteolytic degradation is also a major pathway of Aβ clearance",
      "key": "014469cd6eee2a8f97a16484bcfbe691",
      "line": 280,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 78,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Extracellular Space": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Extracellular Aβ degrading enzymes include neprilysin (NEP), insulin-degrading enzyme (IDE), matrix metalloproteinases (MMPs), angiotensin converting enzyme (ACE), endothelin-converting enzyme (ECE), and plasmin (Baranello et al. 2015)",
      "key": "d070021d59e74a3969cbad94b2a57c6b",
      "line": 290,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 117,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "NEP, plasma membrane glycoprotein, is a zinc metalloendopeptidase and the most efficient hydrolytic enzyme in degrading Aβ in vitro (Shirotani et al. 2001)",
      "key": "d2c35ca711c76464ac1cda2039af77ae",
      "line": 303,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 117,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "And in APP transgenic mice, long-term gene therapy of NEP ameliorates behavior by lowering the levels of Aβ (Spencer et al. 2008)",
      "key": "07d5dbc517efc253440c260a85a3344f",
      "line": 311,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 117,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Exercise training can increase extracellular Aβ clearance in the brains of Tg2576 mice in a dose-dependent manner through up-regulating NEP, IDE, MMP9, LRP1, and HSP70 (Moore et al. 2016)",
      "key": "bb19ed1e4d3db916a37540321fce6791",
      "line": 897,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 117,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Anti-inflammatory mediator annexin A1 (ANXA1) can reduce Aβ content by increasing its degradation by NEP (Ries et al. 2016)",
      "key": "a4ae6287f52599d1b05eba9387f6f5da",
      "line": 978,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 117,
      "subject": {
        "modifier": "Activity"
      },
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "And in APP transgenic mice, long-term gene therapy of NEP ameliorates behavior by lowering the levels of Aβ (Spencer et al. 2008)",
      "key": "c7a5092c882f498c699d537473be9510",
      "line": 312,
      "relation": "increases",
      "source": 117,
      "target": 76
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Extracellular Space": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Extracellular Aβ degrading enzymes include neprilysin (NEP), insulin-degrading enzyme (IDE), matrix metalloproteinases (MMPs), angiotensin converting enzyme (ACE), endothelin-converting enzyme (ECE), and plasmin (Baranello et al. 2015)",
      "key": "8e564f341c926b5ed87957bdba11ded3",
      "line": 291,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 112,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "IDE, a zinc endopeptidase, can degrade extracellular Aβ (Vekrellis et al. 2000)",
      "key": "9b2a7b7c6467c33e6463654a1633c970",
      "line": 317,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 112,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Exercise training can increase extracellular Aβ clearance in the brains of Tg2576 mice in a dose-dependent manner through up-regulating NEP, IDE, MMP9, LRP1, and HSP70 (Moore et al. 2016)",
      "key": "264afbdb32bb5631ca1ba6abcb71eac9",
      "line": 898,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 112,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Meanwhile, an animal experiment showed that IDE expression will descend with age and diabetes, then resulting in Aβ deposition (Kochkina et al. 2015)",
      "key": "dac59b21d0b07c85abad19637ac2eefc",
      "line": 323,
      "relation": "negativeCorrelation",
      "source": 112,
      "target": 74
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Meanwhile, an animal experiment showed that IDE expression will descend with age and diabetes, then resulting in Aβ deposition (Kochkina et al. 2015)",
      "key": "19d1e94fb3d56f33aad5f89b6dc2bbb9",
      "line": 325,
      "relation": "negativeCorrelation",
      "source": 112,
      "target": 139
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Extracellular Space": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Extracellular Aβ degrading enzymes include neprilysin (NEP), insulin-degrading enzyme (IDE), matrix metalloproteinases (MMPs), angiotensin converting enzyme (ACE), endothelin-converting enzyme (ECE), and plasmin (Baranello et al. 2015)",
      "key": "54c8fc94cc602883cf4e46665b58ea41",
      "line": 292,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 91,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Extracellular Space": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Extracellular Aβ degrading enzymes include neprilysin (NEP), insulin-degrading enzyme (IDE), matrix metalloproteinases (MMPs), angiotensin converting enzyme (ACE), endothelin-converting enzyme (ECE), and plasmin (Baranello et al. 2015)",
      "key": "4f145500a65dff5ebc0bded914868119",
      "line": 293,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 96,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "In addition, ACE expression also enhances Aβ clearance, and the levels and activity of ACE are elevated in AD brains (Barnes et al. 1991; Hemming and Selkoe 2005)",
      "key": "4039738b9eeb869e31d88bc71692fe89",
      "line": 344,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 96,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "ACE, a membrane-bound zinc metalloprotease, catalyzes the transformation of angiotensin I to angiotensin II, which is beneficial to the maintenance of body fluid, blood pressure, and sodium balance",
      "key": "cf5facd05649b9df2c988811d140a1f1",
      "line": 334,
      "relation": "increases",
      "source": 96,
      "target": 145
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "ACE, a membrane-bound zinc metalloprotease, catalyzes the transformation of angiotensin I to angiotensin II, which is beneficial to the maintenance of body fluid, blood pressure, and sodium balance",
      "key": "5d7440579f3b10ff48fd87d963af232b",
      "line": 335,
      "relation": "regulates",
      "source": 96,
      "target": 40
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "ACE, a membrane-bound zinc metalloprotease, catalyzes the transformation of angiotensin I to angiotensin II, which is beneficial to the maintenance of body fluid, blood pressure, and sodium balance",
      "key": "d88f45234b503f0479646ff583033139",
      "line": 336,
      "relation": "regulates",
      "source": 96,
      "target": 79
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "ACE, a membrane-bound zinc metalloprotease, catalyzes the transformation of angiotensin I to angiotensin II, which is beneficial to the maintenance of body fluid, blood pressure, and sodium balance",
      "key": "4a807a439bebd6e7b1ab38fc4d040aa9",
      "line": 337,
      "relation": "regulates",
      "source": 96,
      "target": 73
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "In addition, ACE expression also enhances Aβ clearance, and the levels and activity of ACE are elevated in AD brains (Barnes et al. 1991; Hemming and Selkoe 2005)",
      "key": "d2430201e967d54cb62bb646e48ec959",
      "line": 345,
      "relation": "positiveCorrelation",
      "source": 96,
      "subject": {
        "modifier": "Activity"
      },
      "target": 137
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Extracellular Space": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Extracellular Aβ degrading enzymes include neprilysin (NEP), insulin-degrading enzyme (IDE), matrix metalloproteinases (MMPs), angiotensin converting enzyme (ACE), endothelin-converting enzyme (ECE), and plasmin (Baranello et al. 2015)",
      "key": "43974099433321521343ce767fe7b752",
      "line": 294,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 109,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Extracellular Space": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Extracellular Aβ degrading enzymes include neprilysin (NEP), insulin-degrading enzyme (IDE), matrix metalloproteinases (MMPs), angiotensin converting enzyme (ACE), endothelin-converting enzyme (ECE), and plasmin (Baranello et al. 2015)",
      "key": "d3dd37050e30bf5254bc3833bdd81897",
      "line": 295,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 126,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Brain plasmin degrades Aβ",
      "key": "55f85de3942a983680a4aeaa958bf830",
      "line": 350,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 126,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "However, the levels and activity of plasmin are reduced in AD brains (Ledesma et al. 2000)",
      "key": "a06d8b3c2a8f535d069380e720e3d83f",
      "line": 355,
      "relation": "negativeCorrelation",
      "source": 126,
      "target": 137
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "However, the levels and activity of plasmin are reduced in AD brains (Ledesma et al. 2000)",
      "key": "fd668abb09189bf1fb79f5b1fb0e6fee",
      "line": 356,
      "relation": "negativeCorrelation",
      "source": 126,
      "subject": {
        "modifier": "Activity"
      },
      "target": 137
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Meanwhile, an animal experiment showed that IDE expression will descend with age and diabetes, then resulting in Aβ deposition (Kochkina et al. 2015)",
      "key": "2212b9e0b67e527de1cefd2982216551",
      "line": 323,
      "relation": "negativeCorrelation",
      "source": 74,
      "target": 112
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Meanwhile, an animal experiment showed that IDE expression will descend with age and diabetes, then resulting in Aβ deposition (Kochkina et al. 2015)",
      "key": "106f4c379e68fe4906b1cae71548e5f6",
      "line": 324,
      "relation": "positiveCorrelation",
      "source": 74,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Meanwhile, an animal experiment showed that IDE expression will descend with age and diabetes, then resulting in Aβ deposition (Kochkina et al. 2015)",
      "key": "6420489b938544068c6ee275f608a542",
      "line": 325,
      "relation": "negativeCorrelation",
      "source": 139,
      "target": 112
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Meanwhile, an animal experiment showed that IDE expression will descend with age and diabetes, then resulting in Aβ deposition (Kochkina et al. 2015)",
      "key": "6c555b69a0aeefdfad86bccd879e866c",
      "line": 326,
      "relation": "positiveCorrelation",
      "source": 139,
      "target": 7
    },
    {
      "key": "55fdb10210120a54190bd355c757e8e4",
      "relation": "hasReactant",
      "source": 145,
      "target": 2
    },
    {
      "key": "cb66c0343bae500e78cd8512d1c50d6f",
      "relation": "hasProduct",
      "source": 145,
      "target": 8
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Among MMPs, MMP-2, -3 and -9, stimulated by Aβ, play important roles in degrading Aβ (Wang et al. 2014)",
      "key": "9a7364fdec522684f0f971d543df3a09",
      "line": 363,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 118,
      "subject": {
        "modifier": "Activity"
      },
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Among MMPs, MMP-2, -3 and -9, stimulated by Aβ, play important roles in degrading Aβ (Wang et al. 2014)",
      "key": "13e6fc970cd63516bd2e897008d56856",
      "line": 365,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 119,
      "subject": {
        "modifier": "Activity"
      },
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Among MMPs, MMP-2, -3 and -9, stimulated by Aβ, play important roles in degrading Aβ (Wang et al. 2014)",
      "key": "57e87fb3e60b3c600b99ad184f833642",
      "line": 367,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 120,
      "subject": {
        "modifier": "Activity"
      },
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Exercise training can increase extracellular Aβ clearance in the brains of Tg2576 mice in a dose-dependent manner through up-regulating NEP, IDE, MMP9, LRP1, and HSP70 (Moore et al. 2016)",
      "key": "86f4b00e841c5234f3ed987b52153f0e",
      "line": 899,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 120,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Aβ is cleared by receptor-mediated microglial phagocytosis and degradation, such as scavenger receptors, chemokine-like receptor 1, toll-like receptors, and G protein-coupled receptors including formyl peptide receptor 2 (Yu and Ye 2015)",
      "key": "88aacd520a7401be2704d34cbf4ab9cb",
      "line": 384,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 49,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Aβ is cleared by receptor-mediated microglial phagocytosis and degradation, such as scavenger receptors, chemokine-like receptor 1, toll-like receptors, and G protein-coupled receptors including formyl peptide receptor 2 (Yu and Ye 2015)",
      "key": "c8abf19c13eea78396b4472def0c92fa",
      "line": 385,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 105,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Aβ is cleared by receptor-mediated microglial phagocytosis and degradation, such as scavenger receptors, chemokine-like receptor 1, toll-like receptors, and G protein-coupled receptors including formyl peptide receptor 2 (Yu and Ye 2015)",
      "key": "671615fbf5bee57ab27ff072f621e969",
      "line": 386,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 92,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Aβ is cleared by receptor-mediated microglial phagocytosis and degradation, such as scavenger receptors, chemokine-like receptor 1, toll-like receptors, and G protein-coupled receptors including formyl peptide receptor 2 (Yu and Ye 2015)",
      "key": "835254285fb3e5cfd2d5e7e727a2dfd5",
      "line": 387,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 48,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Aβ is cleared by receptor-mediated microglial phagocytosis and degradation, such as scavenger receptors, chemokine-like receptor 1, toll-like receptors, and G protein-coupled receptors including formyl peptide receptor 2 (Yu and Ye 2015)",
      "key": "bb1e68c802f9352a0d841e55a29f772d",
      "line": 388,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 110,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "In addition, triggering receptor expressed on myeloid cells 2 (TREM2), ATP-binding cassette transporter A7, and CD33 also play key roles in microglial phagocytosis",
      "key": "41d22e76146ef7feee4ad9a0090e426e",
      "line": 395,
      "relation": "association",
      "source": 129,
      "target": 77
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "In addition, Aβ1–42 can increase the expression of TREM2, a surface signaling receptor in microglia, and the up-regulation of TRME2 can facilitate microglial phagocytosis of Aβ1–42",
      "key": "f57f8a35a9835430eb5dc5de039847db",
      "line": 406,
      "relation": "increases",
      "source": 129,
      "target": 77
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "In addition, Aβ1–42 can increase the expression of TREM2, a surface signaling receptor in microglia, and the up-regulation of TRME2 can facilitate microglial phagocytosis of Aβ1–42",
      "key": "95b0f51322a7303cec4efdd29ffb110c",
      "line": 405,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 129,
      "subject": {
        "modifier": "Activity"
      },
      "target": 6
    },
    {
      "key": "5affb3c56e29133b862d3c285861aeff",
      "relation": "hasVariant",
      "source": 129,
      "target": 130
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "In addition, triggering receptor expressed on myeloid cells 2 (TREM2), ATP-binding cassette transporter A7, and CD33 also play key roles in microglial phagocytosis",
      "key": "eea230a3d3eec2568dc5269f99b77537",
      "line": 396,
      "relation": "association",
      "source": 94,
      "target": 77
    },
    {
      "annotations": {
        "Cell": {
          "microglial cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "A recent study has shown that ABCA7, mainly expressed in human microglial cells, also regulates microglial phagocytic function and decreases Aβ deposition (Zhao et al. 2015a)",
      "key": "0ce5781b53761fb7091e6dca5d23af6a",
      "line": 427,
      "relation": "regulates",
      "source": 94,
      "target": 77
    },
    {
      "annotations": {
        "Cell": {
          "microglial cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "A recent study has shown that ABCA7, mainly expressed in human microglial cells, also regulates microglial phagocytic function and decreases Aβ deposition (Zhao et al. 2015a)",
      "key": "dc9b41c0839710e1f15e317eaefe76f0",
      "line": 428,
      "relation": "decreases",
      "source": 94,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "However, current evidence showed that ATP-binding cassette transporter A7 deficit can increase Aβ deposition in brain by promoting Aβ-production through increasing β-secretase 1 levels rather than influencing the clearance of Aβ in APP/PS1 mice (Sakae et al. 2016)",
      "key": "e5913c67b749b93a416fcf382a55a412",
      "line": 439,
      "relation": "decreases",
      "source": 94,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "However, current evidence showed that ATP-binding cassette transporter A7 deficit can increase Aβ deposition in brain by promoting Aβ-production through increasing β-secretase 1 levels rather than influencing the clearance of Aβ in APP/PS1 mice (Sakae et al. 2016)",
      "key": "81834e9d18262545666058a37c229f96",
      "line": 440,
      "relation": "decreases",
      "source": 94,
      "target": 101
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "In addition, triggering receptor expressed on myeloid cells 2 (TREM2), ATP-binding cassette transporter A7, and CD33 also play key roles in microglial phagocytosis",
      "key": "7e8e26de9268c801bae16b47fb553985",
      "line": 397,
      "relation": "association",
      "source": 103,
      "target": 77
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Besides, CD33, most abundantly expressed in microglia in AD, inhibits normal function of immune cells and impairs microglia-mediated clearance of Aβ (Jiang et al. 2014b)",
      "key": "5b6c52ce5c179dcae95720598a817b83",
      "line": 448,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "decreases",
      "source": 103,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "In addition, Aβ1–42 can increase the expression of TREM2, a surface signaling receptor in microglia, and the up-regulation of TRME2 can facilitate microglial phagocytosis of Aβ1–42",
      "key": "96ecb6c359fbff66a83d47340ee2895b",
      "line": 404,
      "relation": "increases",
      "source": 6,
      "target": 129
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "However, due to the presence of the R47H mutation in AD, TREM2 cannot effectively recognize the lipid ligands and then fails to activate microglia, which leads to Aβ deposition (Jiang et al. 2014a; Jiang et al. 2013)",
      "key": "fbcc147c60317203b08059510ad6a011",
      "line": 416,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 130,
      "target": 57
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "However, due to the presence of the R47H mutation in AD, TREM2 cannot effectively recognize the lipid ligands and then fails to activate microglia, which leads to Aβ deposition (Jiang et al. 2014a; Jiang et al. 2013)",
      "key": "3e87008b7ecfaf244d16cde961da978b",
      "line": 417,
      "relation": "increases",
      "source": 130,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "LRP1, efflux transporter protein, is expressed mainly at the abluminal membrane of the BBB and highly expressive LRP1 can elevate the rate of Aβ clearance from brain to blood (Pflanzner et al. 2011)",
      "key": "130a84fdb876eb0c898885b68a377649",
      "line": 468,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "Brain",
            "namespace": "MESH"
          },
          "toLoc": {
            "name": "Blood",
            "namespace": "MESH"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 113,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Blood-Brain Barrier": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "GLUT1, glucose transporter expressed in the BBB, regulates LRP1-dependent Aβ clearance via increasing the expression of LRP1",
      "key": "b5f84dd73f4db0171d6fa7be477eb71f",
      "line": 496,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 113,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Exercise training can increase extracellular Aβ clearance in the brains of Tg2576 mice in a dose-dependent manner through up-regulating NEP, IDE, MMP9, LRP1, and HSP70 (Moore et al. 2016)",
      "key": "faff58d71835f64e3ae0b656b8158909",
      "line": 900,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 113,
      "target": 7
    },
    {
      "annotations": {
        "Cell": {
          "blood vessel endothelial cell": true
        },
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "PICALM, mainly expressed in endothelial cells of vascular walls, contributes to the transport of Aβ across the BBB into blood (Xu et al. 2015)",
      "key": "5ff9cc0d0b505d88a77a96065f5e88b3",
      "line": 476,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "Blood-Brain Barrier",
            "namespace": "MESH"
          },
          "toLoc": {
            "name": "Blood",
            "namespace": "MESH"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 122,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "And in AD, the decreasing expression of PICALM in brain endothelium reduces Aβ clearance (Zhao et al. 2015b)",
      "key": "285cb4b03cd9442d45cdd6c56579ad97",
      "line": 486,
      "relation": "decreases",
      "source": 122,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "And in AD, the decreasing expression of PICALM in brain endothelium reduces Aβ clearance (Zhao et al. 2015b)",
      "key": "734518f12602e94df6bcf0f120787277",
      "line": 485,
      "relation": "negativeCorrelation",
      "source": 122,
      "target": 137
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Blood-Brain Barrier": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "GLUT1, glucose transporter expressed in the BBB, regulates LRP1-dependent Aβ clearance via increasing the expression of LRP1",
      "key": "ddff1aec9de35058f3d8e23340f1cfc0",
      "line": 495,
      "relation": "increases",
      "source": 127,
      "target": 113
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Blood-Brain Barrier": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "GLUT1, glucose transporter expressed in the BBB, regulates LRP1-dependent Aβ clearance via increasing the expression of LRP1",
      "key": "0b1cc9eaf55dfaedb9598739333d0a40",
      "line": 497,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "regulates",
      "source": 127,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "In addition, the transport of GLUT1-mediated glucose into the brain is also beneficial to maintaining the integrity of the BBB, thereby ensuring the normal transport of Aβ from brain into blood (Winkler et al. 2015)",
      "key": "b6110c1931954853390109cc7640300c",
      "line": 509,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "Brain",
            "namespace": "MESH"
          },
          "toLoc": {
            "name": "Blood",
            "namespace": "MESH"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "regulates",
      "source": 127,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "In addition, the transport of GLUT1-mediated glucose into the brain is also beneficial to maintaining the integrity of the BBB, thereby ensuring the normal transport of Aβ from brain into blood (Winkler et al. 2015)",
      "key": "81dc71038bed6ff4eda59be737749ec2",
      "line": 507,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "extracellular region",
            "namespace": "GO"
          },
          "toLoc": {
            "name": "Blood-Brain Barrier",
            "namespace": "MESH"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "regulates",
      "source": 127,
      "target": 20
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "In addition, the transport of GLUT1-mediated glucose into the brain is also beneficial to maintaining the integrity of the BBB, thereby ensuring the normal transport of Aβ from brain into blood (Winkler et al. 2015)",
      "key": "209922bc9b1121d9ca2389983b168ec1",
      "line": 508,
      "relation": "regulates",
      "source": 127,
      "target": 39
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "And meanwhile, P-glycoprotein (Pgp), as an efflux transporter, highly expressed on the lumen surface of the BBB, has been proven to transport Aβ out of brain (van Assema et al. 2012; Wei et al. 2016)",
      "key": "abd0e46a96a5070e7df3382bf877c3ff",
      "line": 517,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "Brain",
            "namespace": "MESH"
          },
          "toLoc": {
            "name": "extracellular region",
            "namespace": "GO"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 95,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "However, recently, it has been reported that the expression and transport activity of P-gp are impaired in sporadic AD as a result of its ubiquitination, internalization, and proteasome-dependent degradation derived from Aβ40 (Chiu et al. 2015; Hartz et al. 2016), which will result in Aβ deposition",
      "key": "2e24901a2f592c713c2acb77413f9e24",
      "line": 528,
      "relation": "decreases",
      "source": 95,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "In addition, the luminal residing receptor for advanced glycation end products (RAGE) is an Aβ influx transporter (Deane et al. 2003)",
      "key": "f5e96d2bf9610f0206a15f1269f55f0e",
      "line": 535,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "extracellular region",
            "namespace": "GO"
          },
          "toLoc": {
            "name": "intracellular",
            "namespace": "GO"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 97,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "There is a study showing that the BCSFB is the primary removal channel compared with arachnoid villi, resulting from the receptor LRP1 expressed in epithelial cells of choroid plexus in the BCSFB (Fujiyoshi et al. 2011)",
      "key": "f79499501656f92c2390e67e62984c27",
      "line": 543,
      "relation": "decreases",
      "source": 37,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "CSF is produced mainly by choroid plexus",
      "key": "e5b76decb5f3c27dba9797cb49913434",
      "line": 548,
      "relation": "increases",
      "source": 43,
      "target": 41
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "It has been shown that choroid plexus dysfunction, due to the reductive expression of epithelial aquaporin-1, a water channel protein, can induce CSF production, which in turn damages Aβ clearance in a triple transgenic mouse model of AD (Gonzalez-Marrero et al. 2015)",
      "key": "f266745066fa6a6e7a73235685fc75c5",
      "line": 557,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 99,
      "target": 43
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "It has been shown that choroid plexus dysfunction, due to the reductive expression of epithelial aquaporin-1, a water channel protein, can induce CSF production, which in turn damages Aβ clearance in a triple transgenic mouse model of AD (Gonzalez-Marrero et al. 2015)",
      "key": "70e91b7566aee98685167d34701087fb",
      "line": 559,
      "relation": "decreases",
      "source": 99,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "In a similar manner, a recent experiment indicated that water influx into the CSF is significantly reduced in AD-patients, which may impair Aβ clearance (Suzuki et al. 2015)",
      "key": "116057c8c45f46531dd30d0cc0481432",
      "line": 567,
      "relation": "decreases",
      "source": 32,
      "subject": {
        "effect": {
          "fromLoc": {
            "name": "extracellular region",
            "namespace": "GO"
          },
          "toLoc": {
            "name": "Cerebrospinal Fluid",
            "namespace": "MESH"
          }
        },
        "modifier": "Translocation"
      },
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Brain": true,
          "Cerebrospinal Fluid": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Moreover, researchers reported that TTR, a transporter protein mainly synthesized in the CP of the brain and secreted into the CSF, can reduce the Aβ contents in brain (Ribeiro et al. 2014), which gives us inspiration that TTR bound to Aβ may be a natural mechanism of brain Aβ clearance",
      "key": "73f2d12be49fd654ad64d7d934c083b9",
      "line": 584,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 82,
      "target": 7
    },
    {
      "key": "b1b0c5032996e2c9c888b4f8cd4e3163",
      "relation": "partOf",
      "source": 131,
      "target": 82
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Later, an experiment on live mice using some special methods has also proved that natural sleep or sleep resulting from anesthesia can increase interstitial space by 60%, thereby speeding up the exchange of CSF-ISF and finally increasing the elimination of Aβ (Xie et al. 2013)",
      "key": "5610a8caaa7d7815e663fd3af989f0fa",
      "line": 636,
      "relation": "decreases",
      "source": 141,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Neck": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "A study suggested that Aβ is removed from CSF to cervical lymph nodes via perineural space of the olfactory nerve (Picken 2001; Pollay 2010)",
      "key": "1a18888a565b7fccdfa27d7b7a77e8a2",
      "line": 644,
      "relation": "decreases",
      "source": 46,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Arteries": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "By measuring Aβ levels in superior vena cava and inferior vena cava, it is clear that Aβ levels are getting lower and lower along the direction of the vein blood flow, and the contents of Aβ40 and total Aβ in artery are significantly less than those in vein, suggesting a part of Aβ40 and total Aβ can be cleared by peripheral organs and tissues, such as the liver, kidney, skin, and the gastrointestinal tract, although there is no change in Aβ42 concentrations (Xiang et al. 2015)",
      "key": "bbfeea267974ac2126a87a25bf504656",
      "line": 664,
      "relation": "decreases",
      "source": 60,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Arteries": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "By measuring Aβ levels in superior vena cava and inferior vena cava, it is clear that Aβ levels are getting lower and lower along the direction of the vein blood flow, and the contents of Aβ40 and total Aβ in artery are significantly less than those in vein, suggesting a part of Aβ40 and total Aβ can be cleared by peripheral organs and tissues, such as the liver, kidney, skin, and the gastrointestinal tract, although there is no change in Aβ42 concentrations (Xiang et al. 2015)",
      "key": "ba4aa55f3f7864fbc416db656d36cc4a",
      "line": 665,
      "relation": "decreases",
      "source": 60,
      "target": 5
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Arteries": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "By measuring Aβ levels in superior vena cava and inferior vena cava, it is clear that Aβ levels are getting lower and lower along the direction of the vein blood flow, and the contents of Aβ40 and total Aβ in artery are significantly less than those in vein, suggesting a part of Aβ40 and total Aβ can be cleared by peripheral organs and tissues, such as the liver, kidney, skin, and the gastrointestinal tract, although there is no change in Aβ42 concentrations (Xiang et al. 2015)",
      "key": "73bb613b155a57aa134ee80e75fc9097",
      "line": 666,
      "relation": "causesNoChange",
      "source": 60,
      "target": 6
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Arteries": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "By measuring Aβ levels in superior vena cava and inferior vena cava, it is clear that Aβ levels are getting lower and lower along the direction of the vein blood flow, and the contents of Aβ40 and total Aβ in artery are significantly less than those in vein, suggesting a part of Aβ40 and total Aβ can be cleared by peripheral organs and tissues, such as the liver, kidney, skin, and the gastrointestinal tract, although there is no change in Aβ42 concentrations (Xiang et al. 2015)",
      "key": "cc34c64eefef5d773dcec3687a600230",
      "line": 667,
      "relation": "decreases",
      "source": 44,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Arteries": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "By measuring Aβ levels in superior vena cava and inferior vena cava, it is clear that Aβ levels are getting lower and lower along the direction of the vein blood flow, and the contents of Aβ40 and total Aβ in artery are significantly less than those in vein, suggesting a part of Aβ40 and total Aβ can be cleared by peripheral organs and tissues, such as the liver, kidney, skin, and the gastrointestinal tract, although there is no change in Aβ42 concentrations (Xiang et al. 2015)",
      "key": "a8c480cc18e18ff84dee1a3e28438554",
      "line": 668,
      "relation": "decreases",
      "source": 44,
      "target": 5
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Arteries": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "By measuring Aβ levels in superior vena cava and inferior vena cava, it is clear that Aβ levels are getting lower and lower along the direction of the vein blood flow, and the contents of Aβ40 and total Aβ in artery are significantly less than those in vein, suggesting a part of Aβ40 and total Aβ can be cleared by peripheral organs and tissues, such as the liver, kidney, skin, and the gastrointestinal tract, although there is no change in Aβ42 concentrations (Xiang et al. 2015)",
      "key": "5136311aa1b2f1f35e9a148154954ce7",
      "line": 669,
      "relation": "causesNoChange",
      "source": 44,
      "target": 6
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "It is known that RBCs can facilitate Aβ clearance relying on complement C3b-dependent adherence to complement receptor 1(CR1) on RBCs (Rogers et al. 2006)",
      "key": "05666dd60daf2122b0161a852bd77cd5",
      "line": 686,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 84,
      "target": 7
    },
    {
      "key": "b9667674fba6b944ffc547e7fcb7c38a",
      "relation": "partOf",
      "source": 106,
      "target": 84
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "In addition, a recent experiment showed that a great deal of Aβ in the blood circulation may combine with serum albumin (Stanyon and Viles 2012), which provided a novel clearance pathway in periphery",
      "key": "e5a8dd4d9c15ba621827734d15798909",
      "line": 700,
      "relation": "decreases",
      "source": 85,
      "target": 7
    },
    {
      "key": "9dd293168ab44d1bc232ee0e97e62bfc",
      "relation": "partOf",
      "source": 50,
      "target": 85
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Tau proteins, microtubule-associated proteins, take part in the formation of microtubules for the sake of maintaining the stability of microtubules",
      "key": "bb935285c261ac660b81bea39812cb20",
      "line": 707,
      "relation": "increases",
      "source": 114,
      "target": 36
    },
    {
      "key": "1cae6098fe2dc984676a394bbaaa05e2",
      "relation": "hasVariant",
      "source": 114,
      "target": 115
    },
    {
      "key": "064f60bbd4e86ec0d71e89e733af2e71",
      "relation": "hasVariant",
      "source": 114,
      "target": 116
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Impairment of 26S proteasome induced by tau can be prevented early in disease through activation of cAMP-PKA signaling, and raising the levels of cAMP with rolipram may enhance tau degradation (Myeku et al. 2016)",
      "key": "5a9fe0f6b4c8cbb0e33b0e6a353733bd",
      "line": 808,
      "relation": "decreases",
      "source": 114,
      "target": 125
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "It has been indicated that intracellular tau proteins are also degraded by autophagy and proteasomal pathways (Wang and Mandelkow 2012)",
      "key": "3f3ec8c5c9157740570b4e95eeb10ceb",
      "line": 713,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 75,
      "target": 114
    },
    {
      "annotations": {
        "Cell": {
          "cerebral cortex neuron": true
        },
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Neuronal PAS domain protein 4 has been found to facilitate the autophagic clearance of endogenous total and phosphorylated tau in cortical neurons of rats",
      "key": "1775a820c049c82e4c169740acc5f640",
      "line": 885,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 75,
      "target": 114
    },
    {
      "annotations": {
        "Cell": {
          "cerebral cortex neuron": true
        },
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Neuronal PAS domain protein 4 has been found to facilitate the autophagic clearance of endogenous total and phosphorylated tau in cortical neurons of rats",
      "key": "9d4c8babf2856841e1754c7fee6507a2",
      "line": 886,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 75,
      "target": 116
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "It has been indicated that intracellular tau proteins are also degraded by autophagy and proteasomal pathways (Wang and Mandelkow 2012)",
      "key": "2d42402e7dfd29cc6b85a4cfece4cf1f",
      "line": 714,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 70,
      "target": 114
    },
    {
      "key": "2a2f26f9adc64037be12bfa823e9b17d",
      "relation": "hasVariant",
      "source": 86,
      "target": 87
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "However, there was a study indicating that calpain-mediated tau cleavage can result in the generation of tau fragments, which may possess neurotoxicity in AD (Ferreira and Bigio 2011)",
      "key": "b1416582074f83c62ef9f3ddb515587f",
      "line": 771,
      "relation": "increases",
      "source": 115,
      "target": 136
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Brain": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Human brain tau can be degraded by the proteases, such as cathepsin-D, amino peptidases, human high temperature requirement serine protease A1 (HTRA1), thrombin, caspases, and calpains (Chesser et al. 2013; Kenessey et al. 1997)",
      "key": "035b1b062ac38714d1f328fa88659beb",
      "line": 756,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 107,
      "target": 114
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Brain": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Human brain tau can be degraded by the proteases, such as cathepsin-D, amino peptidases, human high temperature requirement serine protease A1 (HTRA1), thrombin, caspases, and calpains (Chesser et al. 2013; Kenessey et al. 1997)",
      "key": "d1d07f9500c5f92884a4a93b2e2ad41a",
      "line": 757,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 53,
      "target": 114
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Brain": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Human brain tau can be degraded by the proteases, such as cathepsin-D, amino peptidases, human high temperature requirement serine protease A1 (HTRA1), thrombin, caspases, and calpains (Chesser et al. 2013; Kenessey et al. 1997)",
      "key": "6ddd6326fb160eb20c1cdc902b46d173",
      "line": 758,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 111,
      "target": 114
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Brain": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Human brain tau can be degraded by the proteases, such as cathepsin-D, amino peptidases, human high temperature requirement serine protease A1 (HTRA1), thrombin, caspases, and calpains (Chesser et al. 2013; Kenessey et al. 1997)",
      "key": "e2c30b334ddbcd78d2b17cebcaea6eb6",
      "line": 759,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 61,
      "target": 114
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Brain": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Human brain tau can be degraded by the proteases, such as cathepsin-D, amino peptidases, human high temperature requirement serine protease A1 (HTRA1), thrombin, caspases, and calpains (Chesser et al. 2013; Kenessey et al. 1997)",
      "key": "5c32afe514e76305668db82217ea0305",
      "line": 760,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 89,
      "target": 114
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Brain": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Human brain tau can be degraded by the proteases, such as cathepsin-D, amino peptidases, human high temperature requirement serine protease A1 (HTRA1), thrombin, caspases, and calpains (Chesser et al. 2013; Kenessey et al. 1997)",
      "key": "844ae447d58a7e5794d520708d10e6b6",
      "line": 761,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 88,
      "target": 114
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "However, there was a study indicating that calpain-mediated tau cleavage can result in the generation of tau fragments, which may possess neurotoxicity in AD (Ferreira and Bigio 2011)",
      "key": "57597e56e67f2ab87dce0fdfcd117c75",
      "line": 770,
      "relation": "increases",
      "source": 88,
      "target": 115
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Tenuigenin could obviously reduce intracerebral Aβ1–40 accumulation in AD mouse brain by increasing the content of 26S proteasome (Chen et al. 2015)",
      "key": "7efee959720117ca62eab29be6717f9f",
      "line": 800,
      "relation": "decreases",
      "source": 62,
      "target": 5
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Tenuigenin could obviously reduce intracerebral Aβ1–40 accumulation in AD mouse brain by increasing the content of 26S proteasome (Chen et al. 2015)",
      "key": "cbba8bdbe8d978731d56c79c40a61bf1",
      "line": 801,
      "relation": "increases",
      "source": 62,
      "target": 125
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Impairment of 26S proteasome induced by tau can be prevented early in disease through activation of cAMP-PKA signaling, and raising the levels of cAMP with rolipram may enhance tau degradation (Myeku et al. 2016)",
      "key": "661e02abc31810f6f46549916ea4f627",
      "line": 809,
      "relation": "increases",
      "source": 64,
      "target": 125
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Impairment of 26S proteasome induced by tau can be prevented early in disease through activation of cAMP-PKA signaling, and raising the levels of cAMP with rolipram may enhance tau degradation (Myeku et al. 2016)",
      "key": "2730f9629c1793076092fd2581b314ed",
      "line": 810,
      "relation": "increases",
      "source": 26,
      "target": 1
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Impairment of 26S proteasome induced by tau can be prevented early in disease through activation of cAMP-PKA signaling, and raising the levels of cAMP with rolipram may enhance tau degradation (Myeku et al. 2016)",
      "key": "2aed7b9bcaa1fe504ed1a68073181514",
      "line": 812,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 26,
      "target": 114
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Impairment of 26S proteasome induced by tau can be prevented early in disease through activation of cAMP-PKA signaling, and raising the levels of cAMP with rolipram may enhance tau degradation (Myeku et al. 2016)",
      "key": "e2322ca56475d3b87a4474084a05c647",
      "line": 811,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 1,
      "target": 114
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Wogonin, rapamycin, and temsirolimus have been considered to improve the activity of autophagy to increase Aβ clearance and inhibit tau phosphorylation via targeting mTOR signaling (Caccamo et al. 2010; Jiang et al. 2014c; Jiang et al. 2014d; Spilman et al. 2010; Zhu andWang 2015)",
      "key": "7690fe597896f2a851de76f19339421e",
      "line": 820,
      "relation": "increases",
      "source": 33,
      "target": 75
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Wogonin, rapamycin, and temsirolimus have been considered to improve the activity of autophagy to increase Aβ clearance and inhibit tau phosphorylation via targeting mTOR signaling (Caccamo et al. 2010; Jiang et al. 2014c; Jiang et al. 2014d; Spilman et al. 2010; Zhu andWang 2015)",
      "key": "89cd120c80af00b7eb714df61c96b5ab",
      "line": 821,
      "relation": "decreases",
      "source": 33,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Wogonin, rapamycin, and temsirolimus have been considered to improve the activity of autophagy to increase Aβ clearance and inhibit tau phosphorylation via targeting mTOR signaling (Caccamo et al. 2010; Jiang et al. 2014c; Jiang et al. 2014d; Spilman et al. 2010; Zhu andWang 2015)",
      "key": "58a31787328dd8f44735a2f768f961e0",
      "line": 822,
      "relation": "decreases",
      "source": 33,
      "target": 116
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Wogonin, rapamycin, and temsirolimus have been considered to improve the activity of autophagy to increase Aβ clearance and inhibit tau phosphorylation via targeting mTOR signaling (Caccamo et al. 2010; Jiang et al. 2014c; Jiang et al. 2014d; Spilman et al. 2010; Zhu andWang 2015)",
      "key": "6bdaeea02edaecdce0e042c051968f19",
      "line": 823,
      "relation": "increases",
      "source": 29,
      "target": 75
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Wogonin, rapamycin, and temsirolimus have been considered to improve the activity of autophagy to increase Aβ clearance and inhibit tau phosphorylation via targeting mTOR signaling (Caccamo et al. 2010; Jiang et al. 2014c; Jiang et al. 2014d; Spilman et al. 2010; Zhu andWang 2015)",
      "key": "ab743489b2f554c1f6c144997a686e91",
      "line": 824,
      "relation": "decreases",
      "source": 29,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Wogonin, rapamycin, and temsirolimus have been considered to improve the activity of autophagy to increase Aβ clearance and inhibit tau phosphorylation via targeting mTOR signaling (Caccamo et al. 2010; Jiang et al. 2014c; Jiang et al. 2014d; Spilman et al. 2010; Zhu andWang 2015)",
      "key": "85e9cce3c3c0b33a176916550bd51ff8",
      "line": 825,
      "relation": "decreases",
      "source": 29,
      "target": 116
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Wogonin, rapamycin, and temsirolimus have been considered to improve the activity of autophagy to increase Aβ clearance and inhibit tau phosphorylation via targeting mTOR signaling (Caccamo et al. 2010; Jiang et al. 2014c; Jiang et al. 2014d; Spilman et al. 2010; Zhu andWang 2015)",
      "key": "e9c0589eb2f3016237c0148c0464987b",
      "line": 826,
      "relation": "increases",
      "source": 16,
      "target": 75
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Wogonin, rapamycin, and temsirolimus have been considered to improve the activity of autophagy to increase Aβ clearance and inhibit tau phosphorylation via targeting mTOR signaling (Caccamo et al. 2010; Jiang et al. 2014c; Jiang et al. 2014d; Spilman et al. 2010; Zhu andWang 2015)",
      "key": "546c0cd7a9f19d4fa184c6b09a52e7bc",
      "line": 827,
      "relation": "decreases",
      "source": 16,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Wogonin, rapamycin, and temsirolimus have been considered to improve the activity of autophagy to increase Aβ clearance and inhibit tau phosphorylation via targeting mTOR signaling (Caccamo et al. 2010; Jiang et al. 2014c; Jiang et al. 2014d; Spilman et al. 2010; Zhu andWang 2015)",
      "key": "18bd4302b726c62eaa26ded30eb828f1",
      "line": 828,
      "relation": "decreases",
      "source": 16,
      "target": 116
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Protein phosphatase 2A agonists are reported to activate autophagy by affecting AMPK and mTORC1 signaling pathways (Magnaudeix et al. 2013)",
      "key": "535d106a8a7989ec98299c200426030b",
      "line": 835,
      "relation": "increases",
      "source": 124,
      "target": 75
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Recent acknowledged drugs can improve autophagy by acting on the process of autophagy-lysosome formation and then increasing tau clearance, such as methylene blue, lithium, and trehalose (Congdon et al. 2012; Kruger et al. 2012; Shimada et al. 2012)",
      "key": "1bb3fb1eca1c9f58f92a826d6785baf8",
      "line": 844,
      "relation": "increases",
      "source": 13,
      "target": 75
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Recent acknowledged drugs can improve autophagy by acting on the process of autophagy-lysosome formation and then increasing tau clearance, such as methylene blue, lithium, and trehalose (Congdon et al. 2012; Kruger et al. 2012; Shimada et al. 2012)",
      "key": "4ccfb3c893802f112bab534db1b8f339",
      "line": 845,
      "relation": "increases",
      "source": 12,
      "target": 75
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Recent acknowledged drugs can improve autophagy by acting on the process of autophagy-lysosome formation and then increasing tau clearance, such as methylene blue, lithium, and trehalose (Congdon et al. 2012; Kruger et al. 2012; Shimada et al. 2012)",
      "key": "c25d5c0a35983f6efe2be05974ca81ab",
      "line": 846,
      "relation": "increases",
      "source": 4,
      "target": 75
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Proteasome inhibitors and trehalose increase autophagy and decrease tau content by up-regulating the expression of cochaperone BAG3 targeting tau to the autophagy pathway for degradation (Lei et al. 2015)",
      "key": "c96627ccc3f59c86fc01b7bbb3be0811",
      "line": 873,
      "relation": "increases",
      "source": 4,
      "target": 75
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Trehalose also can reduce Aβ levels in hippocampus (Du et al. 2013)",
      "key": "208347c94552ffec465fd89c59e30d3a",
      "line": 852,
      "relation": "decreases",
      "source": 4,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Proteasome inhibitors and trehalose increase autophagy and decrease tau content by up-regulating the expression of cochaperone BAG3 targeting tau to the autophagy pathway for degradation (Lei et al. 2015)",
      "key": "2e73952333efa9968e67873d0474ac1e",
      "line": 874,
      "relation": "decreases",
      "source": 4,
      "target": 114
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Proteasome inhibitors and trehalose increase autophagy and decrease tau content by up-regulating the expression of cochaperone BAG3 targeting tau to the autophagy pathway for degradation (Lei et al. 2015)",
      "key": "d22b308a43daa193045b9e871a2d9559",
      "line": 875,
      "relation": "increases",
      "source": 4,
      "target": 102
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Epigallocatechin-3-gallate enhances the clearance of AD relevant phosphorylated tau species via increasing mRNA expression of autophagy adaptor proteins NDP52 and p62 (Chesser et al. 2016)",
      "key": "591e639c7dd6f37b355e46fbfef0519a",
      "line": 861,
      "relation": "decreases",
      "source": 0,
      "target": 116
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Epigallocatechin-3-gallate enhances the clearance of AD relevant phosphorylated tau species via increasing mRNA expression of autophagy adaptor proteins NDP52 and p62 (Chesser et al. 2016)",
      "key": "6f8f1f91262454d2de08e962af0f3fa8",
      "line": 862,
      "relation": "increases",
      "source": 0,
      "target": 143
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Epigallocatechin-3-gallate enhances the clearance of AD relevant phosphorylated tau species via increasing mRNA expression of autophagy adaptor proteins NDP52 and p62 (Chesser et al. 2016)",
      "key": "adf5ed4fd0748ad570060b7b06d9aba1",
      "line": 863,
      "relation": "increases",
      "source": 0,
      "target": 144
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Proteasome inhibitors and trehalose increase autophagy and decrease tau content by up-regulating the expression of cochaperone BAG3 targeting tau to the autophagy pathway for degradation (Lei et al. 2015)",
      "key": "e19494100bd95d674e6cb4744955dcde",
      "line": 870,
      "relation": "increases",
      "source": 15,
      "target": 75
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Proteasome inhibitors and trehalose increase autophagy and decrease tau content by up-regulating the expression of cochaperone BAG3 targeting tau to the autophagy pathway for degradation (Lei et al. 2015)",
      "key": "4b68aa1d372b3e379b656a5e59d688aa",
      "line": 871,
      "relation": "decreases",
      "source": 15,
      "target": 114
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Proteasome inhibitors and trehalose increase autophagy and decrease tau content by up-regulating the expression of cochaperone BAG3 targeting tau to the autophagy pathway for degradation (Lei et al. 2015)",
      "key": "861f5fdded8dbe5bcf84c7bf267f4775",
      "line": 872,
      "relation": "increases",
      "source": 15,
      "target": 102
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Proteasome inhibitors and trehalose increase autophagy and decrease tau content by up-regulating the expression of cochaperone BAG3 targeting tau to the autophagy pathway for degradation (Lei et al. 2015)",
      "key": "b2f6774196dcd7896f2782f7789b8680",
      "line": 876,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 102,
      "target": 114
    },
    {
      "annotations": {
        "Cell": {
          "cerebral cortex neuron": true
        },
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Neuronal PAS domain protein 4 has been found to facilitate the autophagic clearance of endogenous total and phosphorylated tau in cortical neurons of rats",
      "key": "648fd73f306d36cbbc1979d8a11a192f",
      "line": 884,
      "relation": "increases",
      "source": 121,
      "target": 75
    },
    {
      "annotations": {
        "Cell": {
          "cerebral cortex neuron": true
        },
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Neuronal PAS domain protein 4 has been found to facilitate the autophagic clearance of endogenous total and phosphorylated tau in cortical neurons of rats",
      "key": "efa079862465e09fefc4ce1982c685ea",
      "line": 887,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 121,
      "target": 114
    },
    {
      "annotations": {
        "Cell": {
          "cerebral cortex neuron": true
        },
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Neuronal PAS domain protein 4 has been found to facilitate the autophagic clearance of endogenous total and phosphorylated tau in cortical neurons of rats",
      "key": "2fc94dc4e714ea56a68228230df2d110",
      "line": 888,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 121,
      "target": 116
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Exercise training can increase extracellular Aβ clearance in the brains of Tg2576 mice in a dose-dependent manner through up-regulating NEP, IDE, MMP9, LRP1, and HSP70 (Moore et al. 2016)",
      "key": "bd26c6b0b63436632695271a914479ed",
      "line": 901,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 90,
      "target": 7
    },
    {
      "annotations": {
        "Cell": {
          "astrocyte": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Statin can lead to extracellular IDE secretion from astrocytes in an autophagy-based unconventional secretory pathway (Glebov and Walter 2012), thus enhancing the extracellular removal of Aβ",
      "key": "639c97eefbf0744a931a3adface3ca22",
      "line": 910,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "intracellular",
            "namespace": "bel"
          },
          "toLoc": {
            "name": "extracellular space",
            "namespace": "bel"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 31,
      "target": 112
    },
    {
      "annotations": {
        "Cell": {
          "astrocyte": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Statin can lead to extracellular IDE secretion from astrocytes in an autophagy-based unconventional secretory pathway (Glebov and Walter 2012), thus enhancing the extracellular removal of Aβ",
      "key": "bf59f29ef8ecabc04dcc9778038b7bb5",
      "line": 911,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 31,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Somatotatin also up-regulates the expression and secretion of IDE in order to enhance Aβ clearance (Tundo et al.2012)",
      "key": "b311cb5f331c0445812584cadb8de6a7",
      "line": 918,
      "relation": "increases",
      "source": 30,
      "target": 112
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Somatotatin also up-regulates the expression and secretion of IDE in order to enhance Aβ clearance (Tundo et al.2012)",
      "key": "215b39f9c5f44c9c133c76e685c3c0aa",
      "line": 919,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 30,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "A recent study showed that omega-3 polyunsaturated fatty acids also increase Aβ degradation by proteases",
      "key": "4d9176c31accd46ee938377739b87aea",
      "line": 925,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 14,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "For example, eicosapentaenoic acid (EPA) can induce the activity of IDE and increase its gene expression, and docosahexaenoic acid (DHA) also directly elevates IDE activity and affects sorting by boosting exosome release of IDE (Grimm et al. 2016)",
      "key": "9b6ec96a39ae7a4db403192a82d86567",
      "line": 933,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 3,
      "target": 112
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "For example, eicosapentaenoic acid (EPA) can induce the activity of IDE and increase its gene expression, and docosahexaenoic acid (DHA) also directly elevates IDE activity and affects sorting by boosting exosome release of IDE (Grimm et al. 2016)",
      "key": "7c36eae7335aff2426cb42dba1efa467",
      "line": 934,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 10,
      "target": 112
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Dietary pre-administration of docosahexaenoic acid prevents RBCs from oxidative damage due to its antioxidative characteristic and also increases Aβ degradation by RBC in a lipid raft-dependent manner (Hashimoto et al. 2015)",
      "key": "1357566d4299b945bf81b10e307e0a0c",
      "line": 1066,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 10,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Dietary pre-administration of docosahexaenoic acid prevents RBCs from oxidative damage due to its antioxidative characteristic and also increases Aβ degradation by RBC in a lipid raft-dependent manner (Hashimoto et al. 2015)",
      "key": "0c262b2b3a5c7d24fe6bd44d4e4bb5dc",
      "line": 1067,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 10,
      "target": 54
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Simvastatin and atorvastatin enhance extracellular Aβ degradation via increasing NEP secretion from astrocytes by activating MAPK/Erk1/2 (Yamamoto et al. 2016)",
      "key": "90e6c41fd3c9659100208a502cea008c",
      "line": 941,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 28,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Simvastatin and atorvastatin enhance extracellular Aβ degradation via increasing NEP secretion from astrocytes by activating MAPK/Erk1/2 (Yamamoto et al. 2016)",
      "key": "edd02e7075838096001f271a63968727",
      "line": 942,
      "relation": "increases",
      "source": 28,
      "target": 63
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Astrocytes": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Simvastatin and atorvastatin enhance extracellular Aβ degradation via increasing NEP secretion from astrocytes by activating MAPK/Erk1/2 (Yamamoto et al. 2016)",
      "key": "c9966a15389d529577dec4e13bdbcaae",
      "line": 946,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "intracellular",
            "namespace": "bel"
          },
          "toLoc": {
            "name": "extracellular space",
            "namespace": "bel"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 28,
      "target": 117
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Simvastatin and atorvastatin enhance extracellular Aβ degradation via increasing NEP secretion from astrocytes by activating MAPK/Erk1/2 (Yamamoto et al. 2016)",
      "key": "1e51512a8c133f1fe4d885b356fe3454",
      "line": 943,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 17,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Simvastatin and atorvastatin enhance extracellular Aβ degradation via increasing NEP secretion from astrocytes by activating MAPK/Erk1/2 (Yamamoto et al. 2016)",
      "key": "0b2603c97bb6f61a286e5e3727c94f69",
      "line": 944,
      "relation": "increases",
      "source": 17,
      "target": 63
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Astrocytes": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Simvastatin and atorvastatin enhance extracellular Aβ degradation via increasing NEP secretion from astrocytes by activating MAPK/Erk1/2 (Yamamoto et al. 2016)",
      "key": "1a4283156944be72af163e14e213c654",
      "line": 947,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "intracellular",
            "namespace": "bel"
          },
          "toLoc": {
            "name": "extracellular space",
            "namespace": "bel"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 17,
      "target": 117
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Nobiletin, a flavone from citrus depressa, leads to gene expression and improves the protein level and activity of NEP in SK-N-SH cells, thus reducing Aβ levels (Fujiwara et al. 2014)",
      "key": "08ec74558da9fad3da1a4f53f940bccc",
      "line": 957,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 22,
      "target": 117
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Nobiletin, a flavone from citrus depressa, leads to gene expression and improves the protein level and activity of NEP in SK-N-SH cells, thus reducing Aβ levels (Fujiwara et al. 2014)",
      "key": "0b4177fc6795564caf7993160476b0e5",
      "line": 958,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 22,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "And ginsenoside Rg1 and granulocyte-colony stimulating factor may up-regulate activities of NEP in retinal cells in an AD mouse model to reduce tau protein pathology (He et al. 2014) (Doi et al.2014).",
      "key": "28f981ee74b4f136e57d5d7e9f880f25",
      "line": 966,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 11,
      "target": 117
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "And ginsenoside Rg1 and granulocyte-colony stimulating factor may up-regulate activities of NEP in retinal cells in an AD mouse model to reduce tau protein pathology (He et al. 2014) (Doi et al.2014).",
      "key": "db4e8ce42c38f406075777ed758da96f",
      "line": 967,
      "relation": "decreases",
      "source": 11,
      "target": 142
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "And ginsenoside Rg1 and granulocyte-colony stimulating factor may up-regulate activities of NEP in retinal cells in an AD mouse model to reduce tau protein pathology (He et al. 2014) (Doi et al.2014).",
      "key": "567f70df4a7aa77ec9e16bf58e81008c",
      "line": 968,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 45,
      "target": 117
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "And ginsenoside Rg1 and granulocyte-colony stimulating factor may up-regulate activities of NEP in retinal cells in an AD mouse model to reduce tau protein pathology (He et al. 2014) (Doi et al.2014).",
      "key": "3fccfdedd0b5221655ec650134b6a9bb",
      "line": 969,
      "relation": "decreases",
      "source": 45,
      "target": 142
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Anti-inflammatory mediator annexin A1 (ANXA1) can reduce Aβ content by increasing its degradation by NEP (Ries et al. 2016)",
      "key": "4b7ccb7cf1e047603b9bd681b0c82fc6",
      "line": 976,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 98,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Anti-inflammatory mediator annexin A1 (ANXA1) can reduce Aβ content by increasing its degradation by NEP (Ries et al. 2016)",
      "key": "163755813c6f7de4c3f4a3384d66425a",
      "line": 977,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 98,
      "target": 117
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Minocycline not only suppresses pro-inflammatory phenotypes of microglia but also promotes their phagocytic clearance of Aβ (El-Shimy et al.2015)",
      "key": "0e383c93b6ad846650768ea85d66d36b",
      "line": 985,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 21,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Fractalkine can keep microglia in the right state via interacting with CX3CR, thus contributing to Aβ clearance",
      "key": "91ad1dd1a72ff674caecbadf96823990",
      "line": 991,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 83,
      "target": 7
    },
    {
      "key": "1198eae1b8cadb29565aa877d072fa04",
      "relation": "partOf",
      "source": 42,
      "target": 83
    },
    {
      "key": "811e6d61353cd0e98c191a6519fbdd00",
      "relation": "partOf",
      "source": 108,
      "target": 83
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Rosiglitazone, a highaffinity agonist for PPARγ, can clear Aβ by activating microglia and promoting its phagocytosis via increasing the levels of CD36, a receptor expressed in it (Escribano et al. 2010)",
      "key": "c0a40353adf2eb87df8e667726795b84",
      "line": 999,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 27,
      "target": 123
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Rosiglitazone, a highaffinity agonist for PPARγ, can clear Aβ by activating microglia and promoting its phagocytosis via increasing the levels of CD36, a receptor expressed in it (Escribano et al. 2010)",
      "key": "f5ae1ef38abb50f0957a6ed20b80fcb5",
      "line": 1000,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 27,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Rosiglitazone, a highaffinity agonist for PPARγ, can clear Aβ by activating microglia and promoting its phagocytosis via increasing the levels of CD36, a receptor expressed in it (Escribano et al. 2010)",
      "key": "c8de530d2f42b736c46e0a23a67033c1",
      "line": 1001,
      "relation": "increases",
      "source": 27,
      "target": 104
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Rosiglitazone, a highaffinity agonist for PPARγ, can clear Aβ by activating microglia and promoting its phagocytosis via increasing the levels of CD36, a receptor expressed in it (Escribano et al. 2010)",
      "key": "7b565728615276ed30356b49e7b09f45",
      "line": 1003,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 27,
      "target": 57
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Rosiglitazone, a highaffinity agonist for PPARγ, can clear Aβ by activating microglia and promoting its phagocytosis via increasing the levels of CD36, a receptor expressed in it (Escribano et al. 2010)",
      "key": "a171c124a91197622141d6d11af20db0",
      "line": 1002,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 104,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Moreover, pioglitazone seems to be an effective therapeutic approach targeting Aβ clearance via similar mechanisms to those of rosiglitazone (Mandrekar-Colucci et al. 2012)",
      "key": "d06a108e5babddcd1ef1973efbcab629",
      "line": 1010,
      "relation": "decreases",
      "source": 24,
      "target": 7
    },
    {
      "annotations": {
        "Anatomy": {
          "central nervous system": true
        },
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "It has been discovered that cromolyn sodium, already used in the cure for asthma, can enter the central nervous system and promote Aβ monomer clearance by microglial phagocytosis (Hori et al. 2015)",
      "key": "edd08b32c9cf875f9d27f2ae8c6ccebc",
      "line": 1019,
      "relation": "decreases",
      "source": 9,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "1,25(OH)2D3, the active form of vitamin D, plays a key role in enhancing transport of Aβ1–40 from the brain to the blood by reducing RAGE levels at the BBB, and also in contributing to periphery clearance by increasing levels of LRP1 both in vivo and in vitro (Guo et al. 2016b)",
      "key": "f756c1d7546117d4d33dd16050433eba",
      "line": 1029,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "Brain",
            "namespace": "MESH"
          },
          "toLoc": {
            "name": "Blood",
            "namespace": "MESH"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 18,
      "subject": {
        "modifier": "Activity"
      },
      "target": 5
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Blood-Brain Barrier": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "1,25(OH)2D3, the active form of vitamin D, plays a key role in enhancing transport of Aβ1–40 from the brain to the blood by reducing RAGE levels at the BBB, and also in contributing to periphery clearance by increasing levels of LRP1 both in vivo and in vitro (Guo et al. 2016b)",
      "key": "589127d536342436704780a6b871bfe2",
      "line": 1031,
      "relation": "decreases",
      "source": 18,
      "target": 97
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "1,25(OH)2D3, the active form of vitamin D, plays a key role in enhancing transport of Aβ1–40 from the brain to the blood by reducing RAGE levels at the BBB, and also in contributing to periphery clearance by increasing levels of LRP1 both in vivo and in vitro (Guo et al. 2016b)",
      "key": "9b31c5943741562cd8bbbe0548097bea",
      "line": 1033,
      "relation": "increases",
      "source": 18,
      "target": 113
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Oleocanthal, a special component of extra-virgin olive oil, increases cerebral clearance of Aβ across the BBB by enhancing the expression of important efflux transport proteins at the BBB containing LRP1 and P-gp, and activating the APOE-dependent Aβ clearance pathway in mice brains (Qosa et al. 2015)",
      "key": "c18acee8e379bfe03bb3b5fdb28a1360",
      "line": 1042,
      "relation": "decreases",
      "source": 23,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Blood-Brain Barrier": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Oleocanthal, a special component of extra-virgin olive oil, increases cerebral clearance of Aβ across the BBB by enhancing the expression of important efflux transport proteins at the BBB containing LRP1 and P-gp, and activating the APOE-dependent Aβ clearance pathway in mice brains (Qosa et al. 2015)",
      "key": "6df15939518bb026f2a10e82b010e479",
      "line": 1044,
      "relation": "increases",
      "source": 23,
      "target": 113
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Blood-Brain Barrier": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Oleocanthal, a special component of extra-virgin olive oil, increases cerebral clearance of Aβ across the BBB by enhancing the expression of important efflux transport proteins at the BBB containing LRP1 and P-gp, and activating the APOE-dependent Aβ clearance pathway in mice brains (Qosa et al. 2015)",
      "key": "a2705c16084d362e7dfd8854c60e792f",
      "line": 1045,
      "relation": "increases",
      "source": 23,
      "target": 95
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Cholinesterase inhibitors donepezil and rivastigmine, upregulating transport proteins P-glycoprotein and LRP1, may improve Aβ clearance in the liver of rats (Mohamed et al. 2015)",
      "key": "df513563ca87d2a02b367dc3e44bd476",
      "line": 1053,
      "relation": "increases",
      "source": 19,
      "target": 95
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Cholinesterase inhibitors donepezil and rivastigmine, upregulating transport proteins P-glycoprotein and LRP1, may improve Aβ clearance in the liver of rats (Mohamed et al. 2015)",
      "key": "c0129032b83595c9b7954a3bddf3cf81",
      "line": 1054,
      "relation": "increases",
      "source": 19,
      "target": 113
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Cholinesterase inhibitors donepezil and rivastigmine, upregulating transport proteins P-glycoprotein and LRP1, may improve Aβ clearance in the liver of rats (Mohamed et al. 2015)",
      "key": "cc03d01cd1bf3a1b75e33bc5f3670b1b",
      "line": 1055,
      "relation": "decreases",
      "source": 19,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Cholinesterase inhibitors donepezil and rivastigmine, upregulating transport proteins P-glycoprotein and LRP1, may improve Aβ clearance in the liver of rats (Mohamed et al. 2015)",
      "key": "bb5a9803f2f37f14824fd8ee57582173",
      "line": 1056,
      "relation": "increases",
      "source": 25,
      "target": 95
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Cholinesterase inhibitors donepezil and rivastigmine, upregulating transport proteins P-glycoprotein and LRP1, may improve Aβ clearance in the liver of rats (Mohamed et al. 2015)",
      "key": "24c81e0c0978bdf1a88832eb83dc1bca",
      "line": 1057,
      "relation": "increases",
      "source": 25,
      "target": 113
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Cao X",
          "Tan L",
          "Xin SH",
          "Yu JT"
        ],
        "date": "2018-10-01",
        "db": "PubMed",
        "db_id": "29626319",
        "db_name": "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.",
        "first": "Xin SH",
        "journal": "Neurotoxicity research",
        "last": "Tan L",
        "pages": "733-748",
        "volume": "34"
      },
      "evidence": "Cholinesterase inhibitors donepezil and rivastigmine, upregulating transport proteins P-glycoprotein and LRP1, may improve Aβ clearance in the liver of rats (Mohamed et al. 2015)",
      "key": "21041fc5502c128e5ffc3fa1a08e8758",
      "line": 1058,
      "relation": "decreases",
      "source": 25,
      "target": 7
    }
  ],
  "multigraph": true,
  "nodes": [
    {
      "bel": "a(CHEBI:\"(-)-epigallocatechin 3-gallate\")",
      "concept": {
        "name": "(-)-epigallocatechin 3-gallate",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "3bb6ae0af6e42cc625143279db9d0952"
    },
    {
      "bel": "a(CHEBI:\"3',5'-cyclic AMP\")",
      "concept": {
        "name": "3',5'-cyclic AMP",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "4cdf734bd40326dd8c20c8efe65e611f"
    },
    {
      "bel": "a(CHEBI:\"Angiotensin I\")",
      "concept": {
        "name": "Angiotensin I",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "6af52f2989caaf4daa5adeac24e9215a"
    },
    {
      "bel": "a(CHEBI:\"all-cis-5,8,11,14,17-icosapentaenoic acid\")",
      "concept": {
        "name": "all-cis-5,8,11,14,17-icosapentaenoic acid",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "e4dd5aa4a41d1f784d7b56a7f406f49a"
    },
    {
      "bel": "a(CHEBI:\"alpha,alpha-trehalose\")",
      "concept": {
        "name": "alpha,alpha-trehalose",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "3260bb15c619878948cdb7e00c5bf398"
    },
    {
      "bel": "a(CHEBI:\"amyloid-beta polypeptide 40\")",
      "concept": {
        "name": "amyloid-beta polypeptide 40",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "9e0dfb730cc36c0afbaa05a340211fda"
    },
    {
      "bel": "a(CHEBI:\"amyloid-beta polypeptide 42\")",
      "concept": {
        "name": "amyloid-beta polypeptide 42",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "ef705fbb8d4e7ba18fb04daf5d329b6b"
    },
    {
      "bel": "a(CHEBI:\"amyloid-beta\")",
      "concept": {
        "name": "amyloid-beta",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "e9557ea6ec74113b73fe23f4bd76b524"
    },
    {
      "bel": "a(CHEBI:\"angiotensin II\")",
      "concept": {
        "name": "angiotensin II",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "17c2386466aa664335d7eeca2063bf1f"
    },
    {
      "bel": "a(CHEBI:\"disodium cromoglycate\")",
      "concept": {
        "name": "disodium cromoglycate",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "93db110edfde9435c698f85cfb955514"
    },
    {
      "bel": "a(CHEBI:\"docosahexaenoic acid\")",
      "concept": {
        "name": "docosahexaenoic acid",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "a27b6efe51f1601d80b7db2cef1fb3be"
    },
    {
      "bel": "a(CHEBI:\"ginsenoside Rg1\")",
      "concept": {
        "name": "ginsenoside Rg1",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "9d7af35162032bc1829bc14275cf61b6"
    },
    {
      "bel": "a(CHEBI:\"lithium(1+)\")",
      "concept": {
        "name": "lithium(1+)",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "8831dd736dba764586a6f105da1c4efb"
    },
    {
      "bel": "a(CHEBI:\"methylene blue\")",
      "concept": {
        "name": "methylene blue",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "7beb4cf796511846dabed14b6118ee48"
    },
    {
      "bel": "a(CHEBI:\"omega-3 fatty acid\")",
      "concept": {
        "name": "omega-3 fatty acid",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "783137ebbc9764c42c2bd11a54e6d049"
    },
    {
      "bel": "a(CHEBI:\"proteasome inhibitor\")",
      "concept": {
        "name": "proteasome inhibitor",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "a5776f001c4e984ca2461496253c12a9"
    },
    {
      "bel": "a(CHEBI:Temsirolimus)",
      "concept": {
        "name": "Temsirolimus",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "e8dc27bffc1ec236af40f51999228847"
    },
    {
      "bel": "a(CHEBI:atorvastatin)",
      "concept": {
        "name": "atorvastatin",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "a8df896064a471b02b85fbfa38c9572f"
    },
    {
      "bel": "a(CHEBI:calcitriol)",
      "concept": {
        "name": "calcitriol",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "26117682e151074c71a3b06cd295d7c6"
    },
    {
      "bel": "a(CHEBI:donepezil)",
      "concept": {
        "name": "donepezil",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "09a116b652169bb3a6e79d234f74875d"
    },
    {
      "bel": "a(CHEBI:glucose)",
      "concept": {
        "name": "glucose",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "8b4d8974cf8c0e5830f78bb44168cf4d"
    },
    {
      "bel": "a(CHEBI:minocycline)",
      "concept": {
        "name": "minocycline",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "125bcfaabefb343792e7934d0acfd34b"
    },
    {
      "bel": "a(CHEBI:nobiletin)",
      "concept": {
        "name": "nobiletin",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "5bb21f529a53d44eafa03c53415fb2bb"
    },
    {
      "bel": "a(CHEBI:oleocanthal)",
      "concept": {
        "name": "oleocanthal",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "1e3c1c6f8e6f3a3e727552c60c4eb1c5"
    },
    {
      "bel": "a(CHEBI:pioglitazone)",
      "concept": {
        "name": "pioglitazone",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "eacc21602d4ffa2f2227fc5a7b9efbfe"
    },
    {
      "bel": "a(CHEBI:rivastigmine)",
      "concept": {
        "name": "rivastigmine",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "cba4a9d79d3c1fd998126a3b26bbe752"
    },
    {
      "bel": "a(CHEBI:rolipram)",
      "concept": {
        "name": "rolipram",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "a7947889b5e74e362acf3e1e2053c57a"
    },
    {
      "bel": "a(CHEBI:rosiglitazone)",
      "concept": {
        "name": "rosiglitazone",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "f12e54218d48ea9a2e49befce5b12ee6"
    },
    {
      "bel": "a(CHEBI:simvastatin)",
      "concept": {
        "name": "simvastatin",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "d605d757fc87b8d6d1b857065350843b"
    },
    {
      "bel": "a(CHEBI:sirolimus)",
      "concept": {
        "name": "sirolimus",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "561f7408129243e1ed091f506ef0dded"
    },
    {
      "bel": "a(CHEBI:somatostatin)",
      "concept": {
        "name": "somatostatin",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "c7c90237a07cbb8714226c65b0d9d02f"
    },
    {
      "bel": "a(CHEBI:statin)",
      "concept": {
        "name": "statin",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "4b1229ef1687c603f6a30fd201c7c6f7"
    },
    {
      "bel": "a(CHEBI:water)",
      "concept": {
        "name": "water",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "e31ca77d03bf761df47ae2a13a76e794"
    },
    {
      "bel": "a(CHEBI:wogonin)",
      "concept": {
        "name": "wogonin",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "126766a5cbc107b5e074471760d90c27"
    },
    {
      "bel": "a(CONSO:\"Tau aggregates\")",
      "concept": {
        "name": "Tau aggregates",
        "namespace": "CONSO"
      },
      "function": "Abundance",
      "id": "8e1da50e6008ffdd1b37825776666311"
    },
    {
      "bel": "a(GO:lysosome)",
      "concept": {
        "name": "lysosome",
        "namespace": "GO"
      },
      "function": "Abundance",
      "id": "36892ed99bb9f299dd60bb1b9f7670be"
    },
    {
      "bel": "a(GO:microtubule)",
      "concept": {
        "name": "microtubule",
        "namespace": "GO"
      },
      "function": "Abundance",
      "id": "0fe6be9622e5650da7dca7cdced2f9db"
    },
    {
      "bel": "a(HP:\"blood-cerebrospinal fluid barrier\")",
      "concept": {
        "name": "blood-cerebrospinal fluid barrier",
        "namespace": "HP"
      },
      "function": "Abundance",
      "id": "31410a3262d68bb135959157e8940aaa"
    },
    {
      "bel": "a(HP:\"glymphatic system\")",
      "concept": {
        "name": "glymphatic system",
        "namespace": "HP"
      },
      "function": "Abundance",
      "id": "586d825227a8c3a718136479bcdb1df4"
    },
    {
      "bel": "a(MESH:\"Blood-Brain Barrier\")",
      "concept": {
        "name": "Blood-Brain Barrier",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "63dcf0f7f45e2c3862eb5a77da5f2627"
    },
    {
      "bel": "a(MESH:\"Body Fluids\")",
      "concept": {
        "name": "Body Fluids",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "04be932f8f185dda59710d9c57a503cd"
    },
    {
      "bel": "a(MESH:\"Cerebrospinal Fluid\")",
      "concept": {
        "name": "Cerebrospinal Fluid",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "4263297d8284632a8fd9bed2470cb4a0"
    },
    {
      "bel": "a(MESH:\"Chemokine CX3CL1\")",
      "concept": {
        "name": "Chemokine CX3CL1",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "2899e167dd77243584916e7bc1d7d829"
    },
    {
      "bel": "a(MESH:\"Choroid Plexus\")",
      "concept": {
        "name": "Choroid Plexus",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "7f11b9f65f40f6f9ba0af733cff97bea"
    },
    {
      "bel": "a(MESH:\"Gastrointestinal Tract\")",
      "concept": {
        "name": "Gastrointestinal Tract",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "56fac56824ca649191e3fe127dc48e27"
    },
    {
      "bel": "a(MESH:\"Granulocyte Colony-Stimulating Factor\")",
      "concept": {
        "name": "Granulocyte Colony-Stimulating Factor",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "9d2e8093e242ed4671867cfde71a28d1"
    },
    {
      "bel": "a(MESH:\"Lymph Nodes\")",
      "concept": {
        "name": "Lymph Nodes",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "154e91a64baf9861d531c6e4bb804334"
    },
    {
      "bel": "a(MESH:\"Neurofibrillary Tangles\")",
      "concept": {
        "name": "Neurofibrillary Tangles",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "1ea09b7aace0ed3a0da3f815bd92b304"
    },
    {
      "bel": "a(MESH:\"Receptors, G-Protein-Coupled\")",
      "concept": {
        "name": "Receptors, G-Protein-Coupled",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "a347b970ae57d82c9df4a364618d6645"
    },
    {
      "bel": "a(MESH:\"Receptors, Scavenger\")",
      "concept": {
        "name": "Receptors, Scavenger",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "c781090b74f11368c936315543393885"
    },
    {
      "bel": "a(MESH:\"Serum Albumin\")",
      "concept": {
        "name": "Serum Albumin",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "bae0053d764e3d998a7e20e6eaa5bf38"
    },
    {
      "bel": "a(MESH:\"Tight Junctions\")",
      "concept": {
        "name": "Tight Junctions",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "a1b6489bb399c6463f67361cab6fa5b7"
    },
    {
      "bel": "a(MESH:\"Ubiquitin-Protein Ligases\")",
      "concept": {
        "name": "Ubiquitin-Protein Ligases",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "c0e801155cc8d0a98af1b09f07630384"
    },
    {
      "bel": "a(MESH:Aminopeptidases)",
      "concept": {
        "name": "Aminopeptidases",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "3cb214367fecf1007c264c2c5e54dde2"
    },
    {
      "bel": "a(MESH:Erythrocytes)",
      "concept": {
        "name": "Erythrocytes",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "6cd4965db6716acce6ee5a223d26ab5c"
    },
    {
      "bel": "a(MESH:Kidney)",
      "concept": {
        "name": "Kidney",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "d81b57c4f1373cf41e5ddc0f719488ca"
    },
    {
      "bel": "a(MESH:Liver)",
      "concept": {
        "name": "Liver",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "e30cfc38f11ab042209eb4fc62bc6a02"
    },
    {
      "bel": "a(MESH:Microglia)",
      "concept": {
        "name": "Microglia",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "4ef490b325b2b1e33e41b4e22e1bd8c6"
    },
    {
      "bel": "a(MESH:Monocytes)",
      "concept": {
        "name": "Monocytes",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "cb51e019d107bf85f8e6744f36d4a5bb"
    },
    {
      "bel": "a(MESH:Proteins)",
      "concept": {
        "name": "Proteins",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "d5c3043be47366598a45199bf0e779a8"
    },
    {
      "bel": "a(MESH:Skin)",
      "concept": {
        "name": "Skin",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "ada1e8c044662d785ea0c36415f3e610"
    },
    {
      "bel": "a(MESH:Thrombin)",
      "concept": {
        "name": "Thrombin",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "0deef8137cba9bc07729d4e8dedf6034"
    },
    {
      "bel": "a(MESH:tenuigenin)",
      "concept": {
        "name": "tenuigenin",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "19f536b8115a6223f7e81937ce44ba32"
    },
    {
      "bel": "bp(GO:\"ERK1 and ERK2 cascade\")",
      "concept": {
        "name": "ERK1 and ERK2 cascade",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "75d747a52ba87daccf3b323ab61c4b72"
    },
    {
      "bel": "bp(GO:\"cAMP-mediated signaling\")",
      "concept": {
        "name": "cAMP-mediated signaling",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "86f0bb4a3e977fe727289f9ea9e697a7"
    },
    {
      "bel": "bp(GO:\"cellular protein catabolic process\")",
      "concept": {
        "name": "cellular protein catabolic process",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "f0c5f874128e7d794c0cba23c51a20bc"
    },
    {
      "bel": "bp(GO:\"cytokine production involved in inflammatory response\")",
      "concept": {
        "name": "cytokine production involved in inflammatory response",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "0211720ec37c835dd274d1ecfd30716f"
    },
    {
      "bel": "bp(GO:\"immune response\")",
      "concept": {
        "name": "immune response",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "a7608eff244d93cdc19d37fbc1489683"
    },
    {
      "bel": "bp(GO:\"inflammatory response\")",
      "concept": {
        "name": "inflammatory response",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "abd32f6c5cca606061975532840db260"
    },
    {
      "bel": "bp(GO:\"lysosomal microautophagy\")",
      "concept": {
        "name": "lysosomal microautophagy",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "90eb39b98afb856fd6df94491e6c8fd1"
    },
    {
      "bel": "bp(GO:\"proteasomal protein catabolic process\")",
      "concept": {
        "name": "proteasomal protein catabolic process",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "93e714476cce4befb498395cb274811e"
    },
    {
      "bel": "bp(GO:\"proteasome-mediated ubiquitin-dependent protein catabolic process\")",
      "concept": {
        "name": "proteasome-mediated ubiquitin-dependent protein catabolic process",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "b58e4046466c9b86040a9e10fd09fca6"
    },
    {
      "bel": "bp(GO:\"response to oxidative stress\")",
      "concept": {
        "name": "response to oxidative stress",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "d501b05a4babb0401c86b84d8abf2db7"
    },
    {
      "bel": "bp(GO:\"sodium ion transmembrane transport\")",
      "concept": {
        "name": "sodium ion transmembrane transport",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "cf9dd75c04ef126983024f72a50436f3"
    },
    {
      "bel": "bp(GO:aging)",
      "concept": {
        "name": "aging",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "77570756b71db14efd4d1aefc49bec11"
    },
    {
      "bel": "bp(GO:autophagy)",
      "concept": {
        "name": "autophagy",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "9efc965fac6a195d0fad26eecddaac05"
    },
    {
      "bel": "bp(GO:behavior)",
      "concept": {
        "name": "behavior",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "77f1822074b59deb82cc4661eb6d5aa5"
    },
    {
      "bel": "bp(GO:phagocytosis)",
      "concept": {
        "name": "phagocytosis",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "7a964edef32244471f3c9f79c2cdfbaf"
    },
    {
      "bel": "bp(GO:proteolysis)",
      "concept": {
        "name": "proteolysis",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "c90f282c86a15f55e0daaf157685ceff"
    },
    {
      "bel": "bp(MESH:\"Blood Pressure\")",
      "concept": {
        "name": "Blood Pressure",
        "namespace": "MESH"
      },
      "function": "BiologicalProcess",
      "id": "fe4965bd3798a9aa6b28451e5d343b76"
    },
    {
      "bel": "complex(FPLX:\"Gamma_secretase\")",
      "concept": {
        "name": "Gamma_secretase",
        "namespace": "FPLX"
      },
      "function": "Complex",
      "id": "3fbbd6c9d628246f0677c254e7846905"
    },
    {
      "bel": "complex(GO:\"TOR complex\")",
      "concept": {
        "name": "TOR complex",
        "namespace": "GO"
      },
      "function": "Complex",
      "id": "976a6d7258c921932630141817703dd2"
    },
    {
      "bel": "complex(a(CHEBI:\"amyloid-beta\"), p(HGNC:TTR))",
      "function": "Complex",
      "id": "6eb9f0eab8db28b9a717ab38205b4dc5",
      "members": [
        {
          "bel": "a(CHEBI:\"amyloid-beta\")",
          "concept": {
            "name": "amyloid-beta",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "e9557ea6ec74113b73fe23f4bd76b524"
        },
        {
          "bel": "p(HGNC:TTR)",
          "concept": {
            "name": "TTR",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "e21b9e732ef5f31c9d4b77e6f9bfd587"
        }
      ]
    },
    {
      "bel": "complex(a(MESH:\"Chemokine CX3CL1\"), p(HGNC:CX3CR1))",
      "function": "Complex",
      "id": "c0cb818be64b62525baf0b3a3c74f6cb",
      "members": [
        {
          "bel": "a(MESH:\"Chemokine CX3CL1\")",
          "concept": {
            "name": "Chemokine CX3CL1",
            "namespace": "MESH"
          },
          "function": "Abundance",
          "id": "2899e167dd77243584916e7bc1d7d829"
        },
        {
          "bel": "p(HGNC:CX3CR1)",
          "concept": {
            "name": "CX3CR1",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "9945cf7492b5fe7f76faadee3f2ad481"
        }
      ]
    },
    {
      "bel": "complex(a(MESH:Erythrocytes), p(HGNC:CR1))",
      "function": "Complex",
      "id": "9a6b032e6077165970db857a5b4d1740",
      "members": [
        {
          "bel": "a(MESH:Erythrocytes)",
          "concept": {
            "name": "Erythrocytes",
            "namespace": "MESH"
          },
          "function": "Abundance",
          "id": "6cd4965db6716acce6ee5a223d26ab5c"
        },
        {
          "bel": "p(HGNC:CR1)",
          "concept": {
            "name": "CR1",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "cbb69db33f2516545af9052d0a0cc0b0"
        }
      ]
    },
    {
      "bel": "composite(a(CHEBI:\"amyloid-beta\"), a(MESH:\"Serum Albumin\"))",
      "function": "Composite",
      "id": "de1fa4e9a371594743da3bfa9a5eb8dc",
      "members": [
        {
          "bel": "a(CHEBI:\"amyloid-beta\")",
          "concept": {
            "name": "amyloid-beta",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "e9557ea6ec74113b73fe23f4bd76b524"
        },
        {
          "bel": "a(MESH:\"Serum Albumin\")",
          "concept": {
            "name": "Serum Albumin",
            "namespace": "MESH"
          },
          "function": "Abundance",
          "id": "bae0053d764e3d998a7e20e6eaa5bf38"
        }
      ]
    },
    {
      "bel": "p(CONSO:\"Tau oligomers\")",
      "concept": {
        "name": "Tau oligomers",
        "namespace": "CONSO"
      },
      "function": "Protein",
      "id": "541ac886014140ca02c1076bebd9f2f9"
    },
    {
      "bel": "p(CONSO:\"Tau oligomers\", pmod(CONSO:hyperphosphorylation))",
      "concept": {
        "name": "Tau oligomers",
        "namespace": "CONSO"
      },
      "function": "Protein",
      "id": "f64c88c6ef229e2f1dbddbb27f7f1fc0",
      "variants": [
        {
          "concept": {
            "name": "hyperphosphorylation",
            "namespace": "CONSO"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(FPLX:CAPN)",
      "concept": {
        "name": "CAPN",
        "namespace": "FPLX"
      },
      "function": "Protein",
      "id": "8c9a7dcf7ac5fd35346e732b074db189"
    },
    {
      "bel": "p(FPLX:Caspase)",
      "concept": {
        "name": "Caspase",
        "namespace": "FPLX"
      },
      "function": "Protein",
      "id": "649bb7ca1bbc820c245be4a8d11553b1"
    },
    {
      "bel": "p(FPLX:HSPA)",
      "concept": {
        "name": "HSPA",
        "namespace": "FPLX"
      },
      "function": "Protein",
      "id": "dca8b3456e99b3941ea4c7def32357fa"
    },
    {
      "bel": "p(FPLX:MMP)",
      "concept": {
        "name": "MMP",
        "namespace": "FPLX"
      },
      "function": "Protein",
      "id": "463cbd3fc40b48207bdb804b0d8e7787"
    },
    {
      "bel": "p(FPLX:TLR)",
      "concept": {
        "name": "TLR",
        "namespace": "FPLX"
      },
      "function": "Protein",
      "id": "e62c181e54963b3dee1ea207fdb0e809"
    },
    {
      "bel": "p(FPLX:UBE2)",
      "concept": {
        "name": "UBE2",
        "namespace": "FPLX"
      },
      "function": "Protein",
      "id": "d885290df20a050d0bdd45c7774cd955"
    },
    {
      "bel": "p(HGNC:ABCA7)",
      "concept": {
        "name": "ABCA7",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "1ca727ace4a0a84587b7844d42f41751"
    },
    {
      "bel": "p(HGNC:ABCB1)",
      "concept": {
        "name": "ABCB1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "9589d1bee328c32597838df3a63cf067"
    },
    {
      "bel": "p(HGNC:ACE)",
      "concept": {
        "name": "ACE",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "a42fa7a0be4ac760f67482e649ad0441"
    },
    {
      "bel": "p(HGNC:AGER)",
      "concept": {
        "name": "AGER",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "6438987a3f1a4ac86a4360bddbf0bc6a"
    },
    {
      "bel": "p(HGNC:ANXA1)",
      "concept": {
        "name": "ANXA1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "0865dd6fb2e70ce19b7befd64a272f89"
    },
    {
      "bel": "p(HGNC:AQP1)",
      "concept": {
        "name": "AQP1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "ecb1afcebf9d7740deba9adb6ce392d9"
    },
    {
      "bel": "p(HGNC:AQP4)",
      "concept": {
        "name": "AQP4",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "7baf9b0141df53566fb1b4733d804b4b"
    },
    {
      "bel": "p(HGNC:BACE1)",
      "concept": {
        "name": "BACE1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "334dd03e9a5f223f13995e497b1c156e"
    },
    {
      "bel": "p(HGNC:BAG3)",
      "concept": {
        "name": "BAG3",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "06ff8e44244e7c8a8052cd0a52bfb007"
    },
    {
      "bel": "p(HGNC:CD33)",
      "concept": {
        "name": "CD33",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "347adc300af0ecdf0466525a3b687b25"
    },
    {
      "bel": "p(HGNC:CD36)",
      "concept": {
        "name": "CD36",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "ce124163793baa7b958ba14fa1cb9a92"
    },
    {
      "bel": "p(HGNC:CMKLR1)",
      "concept": {
        "name": "CMKLR1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "6b2f3145cf62e36a82f57b373253f2b1"
    },
    {
      "bel": "p(HGNC:CR1)",
      "concept": {
        "name": "CR1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "cbb69db33f2516545af9052d0a0cc0b0"
    },
    {
      "bel": "p(HGNC:CTSD)",
      "concept": {
        "name": "CTSD",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "c45e8ddad24c8769fb922f3dc70393f9"
    },
    {
      "bel": "p(HGNC:CX3CR1)",
      "concept": {
        "name": "CX3CR1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "9945cf7492b5fe7f76faadee3f2ad481"
    },
    {
      "bel": "p(HGNC:ECE1)",
      "concept": {
        "name": "ECE1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "ed34302995af0526bb1e3e46e42f0ea6"
    },
    {
      "bel": "p(HGNC:FPR2)",
      "concept": {
        "name": "FPR2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "105275e007a7b00beb6a05b2898fc565"
    },
    {
      "bel": "p(HGNC:HTRA1)",
      "concept": {
        "name": "HTRA1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "964e18a1cf592c9913c5c5b11721988f"
    },
    {
      "bel": "p(HGNC:IDE)",
      "concept": {
        "name": "IDE",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "1b1adb12a1eb23245eaa21ff477ee4c5"
    },
    {
      "bel": "p(HGNC:LRP1)",
      "concept": {
        "name": "LRP1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "068524d49458533342e2e490606d63eb"
    },
    {
      "bel": "p(HGNC:MAPT)",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "7d1009217050e75d549c8c5aa83309a8"
    },
    {
      "bel": "p(HGNC:MAPT, frag(\"?\"))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "0e5482dedf92cd5d40eea427059d067d",
      "variants": [
        {
          "kind": "frag",
          "missing": "?"
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "a8fb3a87d5a0672c07462bb17c8b0947",
      "variants": [
        {
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HGNC:MME)",
      "concept": {
        "name": "MME",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "04750748cf48f0571332caef677ccd34"
    },
    {
      "bel": "p(HGNC:MMP2)",
      "concept": {
        "name": "MMP2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "78511410fc96842c39ecd264fc2ea9e0"
    },
    {
      "bel": "p(HGNC:MMP3)",
      "concept": {
        "name": "MMP3",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "e3408dd2587dc1d684573dd9d31a489e"
    },
    {
      "bel": "p(HGNC:MMP9)",
      "concept": {
        "name": "MMP9",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "d2dacdba7b2b8a703a224d03f2f2fb98"
    },
    {
      "bel": "p(HGNC:NPAS4)",
      "concept": {
        "name": "NPAS4",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "744b369c375e0828e758c2fa65cb9e22"
    },
    {
      "bel": "p(HGNC:PICALM)",
      "concept": {
        "name": "PICALM",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "03d6811a2574eba4e6224119733b3385"
    },
    {
      "bel": "p(HGNC:PPARG)",
      "concept": {
        "name": "PPARG",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "3c576f271f63bfbdadb98704c5b62fff"
    },
    {
      "bel": "p(HGNC:PPP2CA)",
      "concept": {
        "name": "PPP2CA",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "2d92165ca8a0570584f2d8e79172e84a"
    },
    {
      "bel": "p(HGNC:PSMD7)",
      "concept": {
        "name": "PSMD7",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "d09dacd1193d8917732b2324772dea2c"
    },
    {
      "bel": "p(HGNC:SERPINF2)",
      "concept": {
        "name": "SERPINF2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "e2ec95ebc5428cbe847fb3a0ae496819"
    },
    {
      "bel": "p(HGNC:SLC2A1)",
      "concept": {
        "name": "SLC2A1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "0685a7a8e864ce5e9ee91d28f007ba7b"
    },
    {
      "bel": "p(HGNC:TFEB)",
      "concept": {
        "name": "TFEB",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "92a32b69c6e6ffc968e227f1caed5786"
    },
    {
      "bel": "p(HGNC:TREM2)",
      "concept": {
        "name": "TREM2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "c3044030c371598598bb85b0321d03ea"
    },
    {
      "bel": "p(HGNC:TREM2, var(\"p.Arg47His\"))",
      "concept": {
        "name": "TREM2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "68860756c0f2313f352bd58907d30108",
      "variants": [
        {
          "hgvs": "p.Arg47His",
          "kind": "hgvs"
        }
      ]
    },
    {
      "bel": "p(HGNC:TTR)",
      "concept": {
        "name": "TTR",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "e21b9e732ef5f31c9d4b77e6f9bfd587"
    },
    {
      "bel": "p(HGNC:UBA1)",
      "concept": {
        "name": "UBA1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "896f4cf81b9e1830416a3260387116f4"
    },
    {
      "bel": "p(HGNC:UBB)",
      "concept": {
        "name": "UBB",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "ab2340dabbb45721478a255d7c84f5f1"
    },
    {
      "bel": "p(HGNC:UBB, var(\"?\"))",
      "concept": {
        "name": "UBB",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "0116abea3122c0d2f77ee7ae87eb4a50",
      "variants": [
        {
          "hgvs": "?",
          "kind": "hgvs"
        }
      ]
    },
    {
      "bel": "p(MESH:\"Ubiquitin-Protein Ligases\")",
      "concept": {
        "name": "Ubiquitin-Protein Ligases",
        "namespace": "MESH"
      },
      "function": "Protein",
      "id": "741e2cfe8a89ad5aa6ad22d433151368"
    },
    {
      "bel": "path(CONSO:neurotoxicity)",
      "concept": {
        "name": "neurotoxicity",
        "namespace": "CONSO"
      },
      "function": "Pathology",
      "id": "f092504a78142cc0cb1a590cf3b073d3"
    },
    {
      "bel": "path(MESH:\"Alzheimer Disease\")",
      "concept": {
        "name": "Alzheimer Disease",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "2ae8307f5fd59056199369691367cc96"
    },
    {
      "bel": "path(MESH:\"Brain Injuries, Traumatic\")",
      "concept": {
        "name": "Brain Injuries, Traumatic",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "3c4b2cad0bdee5fabf9b605909a70f3b"
    },
    {
      "bel": "path(MESH:\"Diabetes Mellitus\")",
      "concept": {
        "name": "Diabetes Mellitus",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "2536452fb299e85b5e69c7e8a161df01"
    },
    {
      "bel": "path(MESH:\"Plaque, Amyloid\")",
      "concept": {
        "name": "Plaque, Amyloid",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "ff45c3caeb411cd232d96d6ed01854d5"
    },
    {
      "bel": "path(MESH:Sleep)",
      "concept": {
        "name": "Sleep",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "93e909729bcb90aaf68722849eb4300c"
    },
    {
      "bel": "path(MESH:Tauopathies)",
      "concept": {
        "name": "Tauopathies",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "e7af59eca49dd3e30ab0fb75db41527a"
    },
    {
      "bel": "r(HGNC:CALCOCO2)",
      "concept": {
        "name": "CALCOCO2",
        "namespace": "HGNC"
      },
      "function": "RNA",
      "id": "c9abf73b3668f9f7c989e4b7877a487f"
    },
    {
      "bel": "r(HGNC:SQSTM1)",
      "concept": {
        "name": "SQSTM1",
        "namespace": "HGNC"
      },
      "function": "RNA",
      "id": "18e18257a276e0f30aaa2b8d0749883e"
    },
    {
      "bel": "rxn(reactants(a(CHEBI:\"Angiotensin I\")), products(a(CHEBI:\"angiotensin II\")))",
      "function": "Reaction",
      "id": "56a45e6a5eab5f1a2df86c48565300b1",
      "products": [
        {
          "bel": "a(CHEBI:\"angiotensin II\")",
          "concept": {
            "name": "angiotensin II",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "17c2386466aa664335d7eeca2063bf1f"
        }
      ],
      "reactants": [
        {
          "bel": "a(CHEBI:\"Angiotensin I\")",
          "concept": {
            "name": "Angiotensin I",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "6af52f2989caaf4daa5adeac24e9215a"
        }
      ]
    }
  ]
}